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Myeloid malignancies are clonal diseases originated of genetic alterations in 
hematopoietic stem or progenitor cells. Application of next-generation sequencing to 
myeloid leukemia has already yielded important discoveries, including the 
identification of common gene mutations (eg, IDH1 and DNTM3A). However, these 
efforts have so far excluded rare myeloid disorders. In this work we used a systematic 
genomic strategy based on whole-exome sequencing, RNA sequencing and target re-
sequencing approaches to provide deeper insights into the genetic pathogenesis of 
blastic transformation of chronic myeloid leukemia, chronic neutrophilic leukemia and 
blastic plasmacytoid dendritic cell neoplasm. 
We identified mutations responsible for these diseases that occur in several 
genes whose encoded proteins belong principally to five classes: signaling pathways 
proteins (e.g. FLT3, RAS), transcription factors (e.g. IKZF family, RUNX1, ZEB2), 
epigenetic regulators (e.g. ASXL1, DNMT3A, IDH1, IDH2, TET2), tumor suppressors (e.g. 
TP53), and components of the spliceosome (e.g. LUC7L2, SF3B1, U2AF1). First, our data 
suggest that sequencing a wider panel of genes that includes ASXL1, TP53 and IKZF 
gene family could be beneficial in the clinical management of non-responders chronic 
myeloid leukemia patients, while current diagnostic procedures recommend the study 
of ABL1 mutations. Second, we show the concurrence of several genetic mechanisms 
that cooperate with the CSF3R mutation in chronic neutrophilic leukemia, such as 
U2AF1, TET2, LUC7L2 and ASXL1 mutations, an altered pattern of splicing in RUNX1 
gene and an expressed fusion gene PIM3-SCO2.  Third, we found that dendritic cell 
leukemia has a mutational profile strikingly similar to that of other well-defined 
myeloid leukemias and patients with mutations in genes in the methylation pathways 
had a significantly reduced cumulative survival. 
In conclusion, large-scale sequencing efforts allowed us the establishment of a 
comprehensive repertoire of these mutations, contributing to an improvement in the 
definition and classification of these myeloid malignancies, and to the identification of 
new prognostic markers and therapeutic targets. 
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Las neoplasias malignas mieloides son enfermedades clonales derivadas de 
alteraciones genéticas en células madre hematopoyéticas. La aplicación de las técnicas 
secuenciación de última generación en el estudio la leucemia mieloide ya ha producido 
importantes descubrimientos como la identificación de mutaciones genéticas 
comunes. Sin embargo, estos esfuerzos han excluido, hasta ahora, los trastornos 
mieloides raros. En este trabajo utilizamos una sistemática estrategia genómica basada 
en la secuenciación masiva del exoma, del ARN total y de genes diana seleccionados 
(re-secuenciación), con el objetivo de proporcionar una mejor comprensión de la 
patogénesis genética de la transformación blástica en la leucemia mieloide crónica, la 
leucemia neutrofílica crónica y la neoplasia de células dendríticas. 
Se identificaron mutaciones responsables de estas enfermedades que se producen en 
genes cuyos productos proteicos pertenecen principalmente a cinco clases de 
proteínas: vías de señalización (FLT3, RAS), factores de transcripción (IKZF familia, 
RUNX1, ZEB2), reguladores epigenéticos (ASXL1, DNMT3A, IDH1, IDH2, TET2), 
supresores tumorales (TP53), y componentes de la maquinaria de splicing (LUC7L2, 
SF3B1, U2AF1). En primer lugar, nuestros datos sugieren que la secuenciación de un 
panel más amplio de genes que incluya ASXL1, TP53 y la familia de genes IKZF podría 
ser beneficiosa para el manejo clínico de los pacientes con leucemia mieloide crónica 
no respondedores. En segundo lugar, se presenta la concurrencia de varios 
mecanismos genéticos, que cooperan con la mutación CSF3R en la leucemia 
neutrofílica crónica, como las mutaciones en U2AF1, TET2, LUC7L2 y ASXL1, un modelo 
diferente de procesamiento del ARN en el gen RUNX1 y un gen de fusión PIM3-SCO2. 
En tercer lugar, hemos encontrado que la leucemia de células dendríticas tiene un 
perfil mutacional sorprendentemente similar al de otras leucemias mieloides bien 
definidas y que los pacientes con mutaciones en los genes en las vías de metilación 
presentaban una supervivencia acumulada significativamente reducida. 
En conclusión, la secuenciación masiva de enfermedades mieloides raras nos permitió 
el establecimiento de un repertorio completo de estas mutaciones, lo que contribuye a 
una mejora en la definición y la clasificación de estas enfermedades, así como a la 
identificación de nuevos marcadores de pronóstico y de dianas terapéuticas. 
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MYELOID MALIGNANCIES are clonal disorders of hematopoietic stem cells, in 
which there is an increased proliferation of the myeloid series, which leads to 
peripheral blood leukocytosis, increased erythrocyte mass or thrombocytosis [1]. This 
heterogeneous group of diseases is divided into five main categories, according to the 
2008 world health organization (WHO): (1) myeloproliferative neoplasms; (2) myeloid 
neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or 
FGFR1; (3) myelodisplastic/myeloproliferative neoplasms; (4) myelodisplastic 
syndrome; and (5) acute myeloid leukemia and related neoplasms (Table 1). The WHO 
classification criteria as well the description of the subtypes of myeloid malignancies 
that were studied in this doctoral thesis are detailed in the following sections. 
1.1 The 2008 World Health Organization (WHO) classification of 
myeloid malignancies 
The WHO classification uses all available information – morphology, 
cytochemistry, immunophenotype, genetics, and clinical features – to define clinically 
significant disease entities. It is a consensus classification in which a number of experts 
have agreed on the classification and the diagnostic criteria used for defining the 
entities that compose it. 
In the WHO classification, the term “myeloid” includes all cells belonging to the 
granulocytic (neutrophil, eosinophil, basophil), monocytic / macrophage, erythroid, 
megakaryocytic and mast cell lineages (Figure 1). The WHO criteria for myeloid 
neoplasms apply to initial diagnostic peripheral blood (PB) and bone marrow (BM) 
specimens obtained prior to any definitive therapy for a suspected hematologic 
neoplasm. Morphologic, cytochemical and/or immunophenotypic features are used for 
establishing the lineage of the neoplastic cells and for assessment of their maturation. 
The blast percentage remains a practical tool for categorizing myeloid neoplasms and 
judging their progression. In the WHO scheme, a myeloid neoplasm with 20% or more 
blasts in the PB or BM is considered to be acute myeloid leukemia (AML) when it 
occurs de novo, evolution to AML when it occurs in the setting of a previously 
diagnosed myelodysplastic syndrome (MDS) or myelodysplastic/ myeloproliferative 
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neoplasm (MDS/MPN), or blast transformation in a previously diagnosed 
myeloproliferative neoplasm (MPN). 
A complete cytogenetic analysis of BM cells is essential during initial evaluation 
for establishing a baseline karyotype; repeat analyses are recommended as needed 
thereafter for judging the response to therapy or for detecting genetic evolution. 
Additional genetic studies should be guided by the results of the initial karyotype and 
by the diagnosis suspected based on the clinical, morphologic, and immunophenotypic 
studies. In some cases, reverse transcriptase–polymerase chain reaction (RT-PCR) 
and/or fluorescence in situ hybridization (FISH) may detect variants of well-recognized 
cytogenetic abnormalities or submicroscopic abnormalities not detected by routine 
karyotyping, such as the FIP1L1-PDGFRA fusion in some myeloid neoplasms associated 
with eosinophilia [2]. In addition, gene mutations are increasingly being recognized as 
important diagnostic and prognostic markers in myeloid neoplasms. These include, 
among others, mutations of JAK2, MPL, and KIT in MPN [3-8]; NRAS, KRAS, NF1, and 
PTPN11 in MDS/MPN [9-14]; NPM1, CEBPA, FLT3, RUNX1, KIT, WT1, and MLL in AML 
[15-19]; and GATA1 [20] in myeloid proliferations associated with Down syndrome. 
Many of these gene mutations figure importantly in the revised WHO classification. 
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Figure 1: Classical hierarchal map of myelopoiesis: formation of myeloid cells from the 
pluripotent hematopoietic stem cells in the bone marrow via myeloid stem cells. Myelopoiesis generally 
refers to the production of leukocytes in blood, such as monocytes and granulocytes. This process also 
produces precursor cells for macrophage and dendritic cells found in the lymphoid tissue (© McGill 
Molson Medical Informatics Project). 
Table 1 lists the major subgroups of myeloid malignancies in the WHO 
classification, and the specific entities of which they are composed. The blue ones are 
entities that were studied in this thesis. 
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Table 1: WHO classification of myeloid neoplasms (adapted from Vardiman et. al. 2009 [21]) 
Myeloproliferative neoplasms (MPN)
Chronic myelogenous leukemia, BCR-ABL1-positive
Chronic neutrophilic leukemia
Polycythemia vera
Primary myelofibrosis
Essential thrombocythemia
Chronic eosinophilic leukemia, not otherwise specified
Mastocytosis
Myeloproliferative neoplasms, unclassifiable
Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA , PDGFRB , or FGFR1
Myeloid neoplasms associated with PDGFRA  rearrangement
Myeloid neoplasms associated with PDGFRB  rearrangement
Myeloid neoplasms associated with FGFR1  abnormalities
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Chronic myelomonocytic leukemia
Atypical chronic myeloid leukemia, BCR-ABL1-negative
Juvenile myelomonocytic leukemia
Myelodysplastic/myeloproliferative neoplasm, unclassifiable
Provisional entity: refractory anemia with ring sideroblasts and thrombocytosis
Myelodysplastic syndrome (MDS)
Refractory cytopenia with unilineage dysplasia
Refractory anemia
Refractory neutropenia
Refractory thrombocytopenia
Refractory anemia with ring sideroblasts
Refractory cytopenia with multilineage dysplasia
Refractory anemia with excess blasts
Myelodysplastic syndrome with isolated del(5q)
Myelodysplastic syndrome, unclassifiable
Childhood myelodysplastic syndrome
Provisional entity: refractory cytopeniaof childhood
Acute myeloid leukemia and related neoplasms
Acute myeloid leukemia with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p22;q23); MLLT3-MLL
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
Acute myeloid leukemia with myelodysplasia-related changes
Therapy-related myeloid neoplasms
Acute myeloid leukemia, not otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemia
Pure erythroid leukemia
Erythroleukemia, erythroid /myeloid
Acute megakaryoblastic leukemia 
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome
Transient abnormal myelopoiesis
Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm  
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1.2 Chronic Myeloid Leukemia (CML) 
Chronic Myeloid leukemia (CML) is a myeloproliferative disorder characterized 
by excessive accumulation of apparently normal myeloid cells. It occurs with an annual 
incidence of 1.0 – 1.5 per 100,000 persons. CML occurs very rarely in children. In the 
Western word, the median age of onset is 50-60 years, which reflects the average age 
of the population [22]. Although symptoms at presentation may include lethargy, 
weight loss, unusual bleeding, sweats, anemia, and splenomegaly, in more develop 
countries, 50% of patients are asymptomatic and are diagnosed as a consequence of 
blood tests performed for unrelated reasons. More than 90% of CML patients are 
diagnosed when their disease is in a relatively early phase know as the chronic phase. 
CML is characterized by distinct clinical phases: most patients present the 
disease in the chronic phase (CP), a phase in which mature granulocytes are still 
produced, but patients have an increased number of myeloid progenitor cells in PB. As 
the disease progresses, patients enter an accelerated phase (AP) followed by a blast 
crisis (BC), in which hematopoietic differentiation has become arrested and immature 
blast accumulate in the BM and spill to the circulation (Figure 2).  It has been 
suggested that the progression of of CP to BC is a two-step process. The initial step for 
chronic phase is the occurrence of Philadelphia chromosome (Ph) and genetic 
instability caused by the BCR-ABL1 tyrosine kinase. The second step is the acquisition 
of additional chromosomal aberrations or mutations of transcription factors by failed 
DNA repair processes. The cellular and molecular mechanism in the CML progression, 
however, are still poorly understood.  
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Figure 2: Natural course of chronic myeloid leukemia. In the chronic phase, the bulk of leukemic stem 
cells remain capable of undergoing differentiation, leading to the excessive production of mature 
granulocytes. In the accelerated phase, differentiation has become arrested, probably at the stage of 
the leukemia progenitor cell, and the ‘aggressive’ disease phenotype is caused by the proliferation (self-
renewal) of immature blasts. Deleterious genetic events are believed to accumulate within stem and 
progenitor cells of the leukemic clone until there are sufficient secondary mutations to drive the 
transition from chronic to advanced phase disease, the blast crisis. These include: an increase in 
genomic instability through interference with genomic surveillance and DNA-repair proteins and a 
progressive telomere shortening (Nature Reviews. 2007. 7:441-53). 
CP is the initial stage of CML, in which most patients are diagnosed. It usually 
has an insidious onset, and the main clinical findings include enlarged spleen, fatigue 
and weight loss. The PB shows leukocytosis (approximately 150 x 109/L white blood 
cells (WBC)), predominantely owing to neutrophils in different stages of maturation, as 
well as basophilia and eosinophilia. Blasts usually represent < 2% of WBC. The platelet 
count is normal or increased. 
At the molecular level, CML-CP is characterized by the presence of the Ph 
chromosome and the oncogene that it encodes is present in the vast majority of 
myeloid cells and some lymphocytes. The Ph chromosome results from a 
t(9;22)(q34;q11) reciprocal translocation that juxtaposes the c-abl oncogene1 (ABL1) 
gene on chromosome 9 with the breakpoint cluster region (BCR) gene on chromosome 
22, generating the BCR-ABL1 fusion oncogene with a greatly enhanced ABL1 kinase 
activity (Figure 3). It is believed that acquisition of the BCR-ABL1 gene occurs initially in 
a single hematopoietic stem cell that gains aproliferative advantage and/or aberrant 
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differentiation capacity over its normal counterparts, giving rise to the expanded 
myeloid compartment. 
AP is an intermediate stage of CML evolution, when the disease starts to 
become refractory to therapy. It is characterized  by an increase in spleen size and in 
total WBC, blasts comprising 10-19% of the WBC, >20% circulating basophils, 
persistent thrombocytopenia and/or the appearance of new clonal cytogenetic 
abnormalities.     
BC is the final stage of CML, which may or may not be preceded by an AP. Patients 
experience worsened performance status, and symptoms related thrombocytopenia, 
anemia and increased spleen enlargement. The WHO criteria for the diagnosis of BC 
include: blast in excess of 20% in the PB or BM; and/or extramedullary blast 
proliferation; and/or large foci or clusters of blasts in BM histological sections. Patients 
with CML-BC have a median survival of approximately 6 months. 
 
Figure 3: t(9;22) and BCR-ABL fusion gene. The Ph chromosome results from a t(9;22)(q34;q11) 
reciprocal translocation that juxtaposes the c-abl oncogene1 (ABL1) gene on chromosome 9 with the 
breakpoint cluster region (BCR) gene on chromosome 22, generating the BCR-ABL1 fusion oncogene 
with a greatly enhanced ABL1 kinase activity (©Terese Winslow). 
The natural history of the disease has damatically changed since 2000 with the 
emergence of tyrosine kinase inhibitors (TKI) that can block the enzymatic action of the 
BCR-ABL1 chimeric protein. The first of these to be developed was Imatinib®. Recent 
karyotype analyses show that 60%–70% of patients achieve complete disappearance of 
Ph-positive marrow cells and maintain exclusively Ph-negative BM cells (a state 
designated as a complete cytogenetic response [CCyR]) 5 years after initiating 
54 
 
Imatinib® treatment. The incidence of progression to a more advanced phase of 
leukemia in patients responding to Imatinib® is extremely low beyond the first two 
years [23]. However, a small number of patients fail to respond to Imatinib® (primary 
resistance), while others respond initially and then lose their response (secondary 
resistance) [24]. The reasons for Imatinib® resistance in CML-CP patients are poorly 
understood. Primary resistance may be related, at least in part, to the intrinsic 
heterogeneity of the disease (e.g., different BCR-ABL1 levels) in different patients and 
to the survival of variable numbers of quiescent cells from which the more mature 
leukemia cells are derived during CP [25]. Secondary resistance may have a wide range 
of causes, of which the best characterized is the acquisition of mutations in the BCR-
ABL1 kinase domain (such as the T315I mutation) [26]. In the last few years, two new 
TKIs, Dasatinib® and Nilotinib®, have become available, both of which are more potent 
in vitro inhibitors of the BCR-ABL1 kinase than Imatinib®. Both of these “second-
generation” TKIs are effective at inducing or restoring CCyR in 40%–50% of patients 
who appear to have failed primary treatment with Imatinib®. However, approximately 
20% of patients presenting with CML-CP fail to respond to both Imatinib® and a 
subsequent second-generation TKI; their prognosis is poor because of a higher risk of 
disease progression. Before the advent of BCR-ABL1 TKIs, all patients with CML-CP 
progressed spontaneously to advanced phase CML after a median interval of 
approximately 5 years.  
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1.3 Chronic Neutrophilic Leukemia (CNL) 
Chronic neutrophilic leukemia (CNL) is a rare MPN, with only ~200 patients 
reported to date, mostly culled from case reports and small case series. Absence of 
both BCR-ABL1 and rearrangement of PDGFRA, PDGFRB or FGFR1 are the minimal 
diagnostic requirements for CNL [21]. The clinical and laboratory features of CNL 
include hepato/splenomegaly, persistent neutrophilic leukocytosis with minimal left-
shift often characterized by toxic granulation and Döhle bodies, and elevated leukocyte 
alkaline phosphatase (LAP) and vitamin B12 levels [21, 27-29]. According to the 2008 
WHO diagnostic criteria for CNL [21], the leukocytosis is ≥ 25x109/L; more than 80% of 
leukocytes are segmented neutrophils / band forms and <10% are immature 
granulocytes. Granulocytic dysplasia is not present, and there is no monocytosis, 
eosinophilia, or basophilia. Examination of the BM shows a myeloid hyperplasia with 
full maturation with <5% myeloblasts (<1% in the PB). Megakaryocytes are typically 
normal, but can include some small hypolobated megakaryocytes. Reticulin fibrosis is 
not significantly increased. Exclusionary criteria include no evidence of a reactive 
neutrophilia, other MPN, MDS, or overlap MDS/MPN disorder [21]. Table 2 
summarizes the 2008 WHO classification for CNL. 
The disease course of CNL is variable, but acceleration is typically characterized 
by refractory neutrophilia, worsening organomegaly, and blastic transformation. In a 
literature review of 40 patients meeting WHO criteria for 'true' CNL, the median 
survival was 23.5 months (range: 1–106) [29]. Median time to AML transformation was 
21 months (range 3-94). The most frequent causes of death were intracranial 
hemorrhage, progressive disease/blastic transformation, and regimen-related toxicity 
from induction chemotherapy or transplantation [28, 29].  
No standard of care exists for CNL. Therapy has primarily consisted of 
hydroxyurea or other oral chemotherapeutics, as well as interferon-alpha [27-34]. 
These agents can elicit improvement in blood counts, but exhibit no proven disease-
modifying benefit. Although splenic irradiation and splenectomy may provide transient 
palliation of symptomatic splenomegaly, the latter has been associated with anecdotal 
worsening of neutrophilic leukocytosis in CNL. The limited experience with induction-
type chemotherapy for blastic transformation is generally poor with death related to 
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resistant disease or regimen-related toxicities. Allogeneic transplantation may result in 
favorable long-term outcomes in selected patients, particularly when undertaken in 
the CP of disease [27-30, 32]. 
Although clonality has been demonstrated in CNL [35, 36], the majority of 
patients exhibit normal cytogenetics [27-29]. In CNL, trisomy 8 and del(20q) are the 
most common non-specific chromosomal abnormalities observed at diagnosis or at the 
time of progressive disease. The e19/a2 type BCR-ABL1 mRNA transcript (p230) that 
was initially reported as the molecular basis for some cases of CNL is instead now 
considered related to an uncommon 'neutrophilic variant' of CML [37]. 
Notwithstanding case reports of JAK2 V617F positivity in selected cases of CNL [34, 38, 
39], no other recurrent genetic mutations had been identified in these diseases until 
the recent discoveries of mutant CSF3R [38]. 
Table 2: WHO diagnostic criteria for CNL (adapted from Vardiman et. al. 2011 [40]) 
1 Peripheral blood leukocytosis (WBC ≥ 25x10
9
/L)
Segmented neuthrophils and band forms are > 80% of the WBC
Immature granulocytes (promyelocytes, myelocytes, metamyelocytes) are <10% of WBC 
Myeloblasts are <1% of WBC
2 Hypercellular BM biopsy
Neutrophilic granulocytes increased in number and percentage
Myeloblasts <5% of nucleated BM cells
Neutrophilic maturation pattern normal
Megakaryocytes normal or left shifted
3 Hepatosplenomegaly
4 No identifiable cause for physiologic neutrophilia or, if present, demostration of clonality
No infectious or inflammatory process
No underlying tumor
5 No Philadelphia chromosome or BCR-ABL1  fusion gene
6 No rearrangements of PDGFRA , PDGFRB , or FGFR1
7 No evidence of polycythemia vera, essential thrombocythemia, or primary myelofibrosis
8 No evidence of MDS or MDS/MPN
No granulocytic dysplasia
No myelodysplastic changes in other myeloid lineages
Monocytes < 1x10
9
/L  
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1.4 Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN) 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously referred as 
“blastic NK-cell lymphoma/leukemia” or “agranular CD4+/CD56+ hematodermic 
neoplasm”, is a rare and aggressive hematologic disease derived from precursors of a 
specialized subset of dendritic cells, and hence, after some discussion, is considered a 
myeloid-related disease according to the 2008 WHO classification of myeloid 
neoplasms [21, 41-46]. These tumor cells infiltrate skin, BM, PB and lymph nodes [47-
50] and mainly affect elderly patients with the maximum incidence peaking at 
approximately 65 years of age.  
 Diagnosis is based on the immunophenotype of the blast cells that are 
characterized by the expression of CD4, CD43, CD56, CD123, BDCA-2/CD303, TCL1, and 
CTLA [51]. In addition, immunohistochemical markers, such as SPIB, BDCA-4, IRF-8, 
BCL11A and CD2AP, have been recently reported as tools for BPDCN diagnosis [51, 52]. 
There are no established genetic biomarkers that assist in the clinical management of 
BPDCN. Preliminary results from molecular studies suggest that abnormalities of genes 
known to confer a poor prognosis in other hematological malignancies, such as 
CDKN2A/CDKN2B, TET2 and TP53, are frequently seen in BPDCN [53, 54]. 
The overall prognosis for BPDCN is remarkably poor. Lymphoid-like 
chemotherapy is the preferred treatment, however, most patient relapse, resulting in 
a median overall survival (OS) of 12-14 months [55, 56]. Only high-dose therapy 
followed by allogeneic stem cell transplantation can provide durable control in this 
otherwise fatal condition [57, 58]. 
1.5 Myeloid Malignancies in the age of genomics 
Since Nowell and Hungerford identified the t(9;22) translocation associated 
with CML [59], a wealth of data has accumulated showing that the karyotype and 
mutation status of certain genes provide important prognostic, and in some cases, 
therapeutic information for myeloid malignancies. However, standard cytogenetics has 
a limited resolution (3-5 megabases - Mb) to detect chromosomal abnormalities and 
genotyping of individual genes is expensive; therefore, as the number of mutations 
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identified in myeloid malignancies increases, this method may soon become 
impractical. During the last decade, the technology to interrogate cancer genomes has 
rapidly advanced. The resolution for variant detection was improved first with array-
based technologies using comparative genome hybridization (CGH) and single 
nucleotide polymorphism (SNP) analysis, and now with whole-genome sequencing 
(WGS), which provides unbiased, genome-wide coverage at a single base-pair 
resolution. Gene-expression profiling and CGH/SNP analyses of myeloid malignancies 
have also provided important insights into its classification and biology [60-62]. 
In the past, the size and complexity of the human genome (3 billion base pairs -
bp) made the sequencing of human cancer genomes impractical. Two major advances 
helped to overcome these obstacles. First, the generation of the draft sequence of the 
human genome by the Human Genome Project in 2001 provided a road map of the 
human genome [63]. Second, technological advances in DNA sequencing that have 
dramatically reduced the cost and time required to sequence genomes. Whereas the 
Human Genome Project took more than 10 years and several billion dollars to 
sequence the first human genome, current estimates are 6 weeks and $20 000 per 
human genome ($40 000 for paired tumor/normal genomes). Therefore, we are 
rapidly approaching the time when sequencing the genomes of patients with cancer 
will be practical in the clinical setting. 
1.5.1 Next-Generation Sequencing (NGS) of Cancer 
The development of massively parallel sequencing (termed next-generation or 
second-generation sequencing) revolutionized our ability to analyze cancer genomes. 
In brief, massively parallel sequencing results in the generation of millions of short (50-
100 nucleotides) DNA sequences simultaneously. These sequences are then mapped 
back to the human reference genome to generate a picture of the cancer genome [64, 
65]. For studies of cancer, it is important to sequence both the tumor and the normal 
tissue (oral mucosa or skin tissue, for example) from the individual. There are 3-4 
million inherited sequence variants per human genome (and hundreds of copy number 
variants). Consequently, the majority of sequence variants identified in a cancer 
genome are composed by inherited polymorphisms and not by acquired mutations. 
Therefore, a comparison of a tumor genome with its paired normal genome is required 
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to efficiently identify acquired (somatic) sequence variants. Currently, there are 
several different ways in which NGS is being applied to study cancer genomes. The 
goals, advantages, and limitations of each approach are summarized below and in 
Table 3. Ultimately, combinations of approaches (whole-genome and transcriptome 
sequencing, for example) may be required to comprehensively study cancer cells.  
1.5.2 Whole-Genome Sequencing (WGS) 
The goal of WGS is to sequence the entire genome. Typically, this requires at 
least 30- to 40-fold haploid coverage of the genome (~100 Gbp of sequence) to achieve 
adequate diploid coverage for comprehensive mutation discovery. The advantages of 
WGS include: (1) the entire genome is surveyed, not just coding genes, and (2) 
structural variants, including deletions, amplifications, chromosomal translocations 
and uniparenteral disomy (UPD), are readily identified. The major limitations are cost 
and the complexity of the data analysis. As costs reduction and bioinformatic 
approaches to analyzing sequence data advance, WGS is likely to become the 
dominant platform for mutation detection. 
1.5.3 Whole-Exome Sequencing (WES) 
The goal of exome sequencing is to selectively sequence the 1%-2% of the 
genome containing coding genes, microRNAs, and other noncoding RNAs. In brief, 
genomic DNA is hybridized to beads (or arrays) containing probes designed to capture 
the approximately 200 000 exons in the human genome. The DNA “captured” on the 
beads is then subjected to next-generation sequencing. The major advantages of 
exome sequencing, compared with WGS, are, for instance, its reduced cost to get 
relatively deep sequence coverage, because only 1%-2% of the genome is analyzed. 
Another important advantage is the higher likelihood of a mutation that is found by 
WES will result in a non-properly functioning protein, making this approach an even 
better cost effective tool for research and clinical translation. However, exome 
sequencing will not detect mutations in regions outside of the exome (~ 98% of the 
genome) and will not detect most structural variants, such as chromosomal 
translocations with intronic break points.  
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1.5.4 Transcriptome sequencing 
The goal of transcriptome sequencing is to sequence all transcribed genes [66], 
including both coding and noncoding RNAs. The advantages of transcriptome 
sequencing include: (1) quantitative information about gene-expression levels are 
obtained, (2) post-transcriptional changes in gene expression such as alternative 
splicing are detected, and (3) fusion transcripts produced by chromosomal 
rearrangements can be detected. Similar to sequencing the exome, transcriptome 
sequencing does not detect mutations in non-coding regions of the genome. It cannot 
detect mutations that cause the loss of one or both copies of a gene or mutations that 
accelerate RNA turnover (frameshift or nonsense mutations that cause “nonsense 
mediated decay”, for example). Moreover, transcriptome sequencing is biased toward 
abundantly expressed transcripts and therefore the sequencing coverage of genes 
expressed at lower levels can be below or absent.  
1.5.5 Other sequencing applications 
There are emerging NGS applications to characterize genome-wide epigenetic 
modifications in cancer cells. This is particularly relevant to the study of AML, because 
genes regulating DNA methylation are frequently mutated in AML, including DNMT3A. 
NGS techniques have been developed to map genome-wide DNA methylation at a 
single-base resolution [67] and to assess chromatin structure by mapping the location 
of post-translationally modified (methylated and acetylated, for example) histones on 
the genome [68]. 
Table 3: Summary of next-generation sequencing assays 
Sequencing target Approach Comment
Comprehensive but expensive; detects point mutations,
indels, translocation, deletions, and amplifications 
Only identifies mutations in exons, misses many structural
variants
RNA is reversed transcribed to generate cDNA and then RNA expression and splicing are assessed; only identifies
sequenced mutations in expressed genes
gDNA is treated with bisulfite to mark methylated cytosines Assay being optimized; provides genome-wide information
before sequencing about gDNA methylation
Histone-associated ChIP using antibodies against modified histones followed Used to assess chromatin modifications, in particular
genome by sequencing genome-wide occupancy by modified histones
Whole genome
Exome
Transcriptome
Methylome
Unselected genomic DNA is fragmented and sequenced
Exonic DNA is enriched by capture and then sequenced
 
61 
 
1.5.6 Current limitations of whole-genome sequencing 
Although clearly a valuable and promising approach to analyzing myeloid 
malignancies (and other cancers), there are some technical limitations of whole-
genome sequencing. The ability of next-generation sequencing to detect sequence 
variants is dependent on the “read-depth,” the number of unique times a single 
nucleotide is sampled. Whole-genome sequencing typically aims to cover each 
nucleotide with an average of 30-40 separate reads. However, at this coverage, nearly 
50% of sequence variants identified are false positives due to mapping errors, 
polymerase errors, and the low frequency of somatic variants within the sample. 
Therefore, secondary validation of variants remains a necessary part of all sequencing 
projects. The detection of small insertions and deletions (indels) using current 
algorithms is problematic. In addition, mapping sequence reads to the approximately 
50% of the human genome that contains repetitive sequences is imperfect, raising the 
possibility that mutations are being missed. The incident AML case highlighted these 
technical issues [69]; a single base-pair deletion in DNMT3A was missed during short-
read analysis (30- to 40-bp reads, which are difficult to align to the reference genome if 
they contain an indel), but was later identified when the genome was re-sequenced 
with paired-end reads (pairs of 50- to 75-bp reads, which align more robustly). These 
problems will be improved as bioinformatics can draw on additional sequenced human 
genomes and as decreased costs permit deeper sequencing, but efficiently mapping 
sequences to repetitive regions of the genome will likely require technical 
improvements that permit longer sequence read lengths.  
There are inherent limitations of whole-genome sequencing that need to be 
considered when analyzing cancers. First, each leukemia genome carries 
approximately 500-1000 somatic mutations [70]. It is likely that the majority of these 
mutations do not contribute to leukemic transformation. Identifying the “driver’” 
mutations in each leukemia genome is currently challenging. Second, whole-genome 
sequencing does not provide information about epigenetic modifications and 
alterations in gene expression. Therefore, to fully characterize acquired genomic 
changes in a patient, assays to measure RNA expression (transcriptome sequencing, 
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for example) and epigenetic changes (e.g., bisulfate sequencing to define the 
methylome) in combination with whole-genome sequencing are still required.  
Genome sequencing remains expensive, and the requisite infrastructure, 
expertise, and time to complete sequence analysis are significant barriers to the 
routine use of WGS in the clinical setting. However, as the number of sequenced 
genomes increases, the technical and bioinformatic infrastructure required for clinical 
analysis will become more accessible. Current cost estimates at the Washington 
University Genome Institute for WGS of a paired normal/leukemia sample is $40 000. 
This is a fully loaded cost that includes sequencing, bioinformatic analysis, and 
validation. The current time to sequence and analyze a paired tumor and normal 
genome is 6 weeks. The cost of WGS needs to be considered in the context of the 
increasingly complex diagnostic evaluation for leukemia. A common molecular 
evaluation of AML consists of cytogenetics; FISH for t(15;17), t(8;21), inv(16), and 
t(9;22); and molecular testing for FLT3, KIT, JAK2 and NPM1. The list price of this 
“standard of care” molecular evaluation at a laboratory is approximately $4500 and 
does not include the cost of molecular testing for other recurring mutations (e.g., 
NRAS, IDH1, IDH2, TET2, DNMT3A, RUNX1, ASXL1, and CEBPA) that are likely to 
become routine. As the cost of sequencing continues to decrease and the number of 
molecular assays continues to increase, we will rapidly reach the inflection point where 
NGS will be the most cost-effective diagnostic tool for leukemia patients.  
Finally, there are important practical and ethical considerations concerning the 
clinical application of WGS. Based on the cancer genomes analyzed to date, it is clear 
that a tremendous number of genetic variants will be identified in each genome, of 
which the majority will be inherited variants. Some of these will be in genes known to 
be involved in cancer susceptibility, and some will be associated with unsuspected 
genetic diseases (e.g., hereditary hemochromatosis). Best practices to communicate 
this information to patients and their families are being considered and developed by 
several groups of investigators. 
1.5.7 Potential clinical applications (current and future) 
NGS provides a method to identify all genetic changes in a cancer genome, 
including single-nucleotide mutations, deletions, amplifications, chromosomal 
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translocations, and UPD, at a single-base resolution. There is several ways that this 
unprecedented ability to characterize cancer genomes may affect the clinical 
management of patients with leukemia. 
• Classification  
NGS may lead to a better classification of leukemias. There is evidence that a 
molecular classification of leukemia based on karyotype and specific gene mutations is 
superior to a morphology-based classification. As additional mutations are discovered 
in leukemias, it is likely that the molecular classification of this disease will be further 
defined. Having access to all of the genetic changes in a genome through WGS would 
facilitate this process.  
• Optimizing therapy  
A detailed knowledge of mutations present in leukemia genome may help to 
optimize the therapeutic plan. For example, mutations in tyrosine kinase genes may 
suggest the use of specific small molecule inhibitors. In addition, disruption of specific 
pathways in the leukemia genome may be exploited therapeutically. For example, 
mutations in BRCA1 or BRCA2, by inhibiting DNA repair through homologous 
recombination, may render cancer cells more sensitive to inhibitors of protein 
poly(ADP)-ribose polymerase [71]. Finally, the discovery of new mutations in leukemia 
may lead to the development of novel targeted therapeutics. 
• Pharmacogenomics 
Pharmacogenomics is the study of how an individual’s genes influence his or 
her response to drugs. Genetic variants can influence the metabolism, toxicity, and 
therapeutic efficacy of a drug. By sequencing the “normal” and leukemia genomes in 
patients with cancer, genetic variants known to affect the efficacy and toxicity of 
chemotherapeutic agents will be identified and this information may affect the choice 
and dose of chemotherapy used. For example, germline polymorphisms in the UDP 
glucuronosyltransferase1 family (UGT1A1) increase the toxic effects of irinotecan [72], 
and germline polymorphisms in thiopurine S-methyltransferase (TMPT) increase 
sensitivity to mercaptopurine through decreased metabolism [73]. As more genomes 
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are sequenced, the list of genetic variants influencing response to chemotherapy likely 
will expand. 
• Cancer susceptibility 
As discussed above, WGS of the “normal” genome in patients with cancer may 
identify genetic variants contributing to cancer susceptibility. Not only will this 
information be important for genetic counseling, it may affect the patients treatment 
and prognosis. WGS will provide genotyping data for the more than 100 genes already 
implicated in cancer susceptibility. Causal associations between germline variants and 
AML have been firmly established for only a few genes, such as TP53 [74] and RUNX1 
[75]. However, it is likely that the list of genetic variants contributing to leukemia 
susceptibility will increase in the near future as additional genomes are sequenced. 
1.5.8 Identification of novel somatic mutations in myeloid malignancies 
by NGS 
Traditional approaches to mutation discovery in cancer rely on sequencing of a 
pre-selected group of genes. Typically, genes or gene family members already 
implicated in cancer are sequenced. This directed sequencing approach (in effect 
“looking under the lamppost”), while yielding important insights into cancer biology is 
inherently limited. In contrast, genomic approaches study the entire cancer genome 
and thus provide a nonbiased way to look for mutations. Moreover, by simultaneously 
evaluating all genes, WGS is an ideal platform to assess cooperativity between gene 
mutations. 
In a study published in 2008, Ley et al reported the sequence of the first 
primary cancer genome, a case of FAB M1-AML [69]. Since then, the sequence of 3 
additional AML genomes have been reported: an additional case of M1-AML (normal 
karyotype) [69, 70, 76] and 1 case each of M3-AML [77] and therapy-related AML 
(complex karyotype) [78]. In addition, exome sequencing was reported in 14 cases of 
M5-AML [79]. 
These studies have begun to define several important global features of AML. 
First, there are only a relatively small number of somatically acquired single nucleotide 
variants (SNVs or “point mutations”) in AML cells. Within coding regions, the number 
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of somatic SNVs ranged from 10-26 in the 4 sequenced AML genomes [69, 70, 76-78]. 
This suggests that AML does not result from genomic instability, but rather may be 
associated with a small number of oncogenic “driver” mutations. Second, most 
acquired AML associated SNVs are private: of the 59 reported SNVs in the coding 
regions of these 4 genomes, no gene was mutated in 2 or more patients. This suggests 
that many of these mutations are likely to be personal “passenger” mutations, which 
are random and do not contribute to AML pathogenesis.  
Despite the lack of recurring mutations within these 4 genomes, these studies 
identified 2 novel AML-associated genes that were found to be frequently mutated in 
AML and contribute to leukemogenesis. Mardis et al identified mutations in IDH1 in 
the second AML genome published and found an additional 16 patients carrying IDH1 
mutations [76]. Mutations in IDH1 and IDH2 have since been identified in AML patients 
in several studies, occur at a frequency of 7%-16%, and appear to be mutually 
exclusive of one another and of acquired TET2 mutations [80, 81]. A recent study 
found that mutations in IDH1 or IDH2 disrupted TET2 function and led to a 
hypermethylation phenotype with impaired hematopoietic differentiation [82], 
although a second study found impaired methylation associated with TET2 mutations 
[83]. Efforts are ongoing to develop targeted therapeutics that might abrogate these 
effects.  
Acquired mutations in DNMT3A, a de novo DNA methyltransferase, were 
identified by NGS of AML samples by 3 independent groups. Yamashita et al used 
targeted-exome sequencing to identify acquired mutations in DNMT3A at amino acid 
R882 in 3 of 71 (4.2%) AML cases [84]. Ley et al identified a single base-pair deletion in 
DNMT3A by WGS and identified acquired mutations (including deletions, frameshifts, 
nonsense, and missense mutations) in an additional 62 of 281 AML patients (22.1%) 
[70]. They showed that DNMT3A mutations were more common in AML with normal 
cytogenetics (33.7%) or M5-AML cytomorphology (57.1%) and were associated with an 
adverse outcome. Finally, Yan et al used WES to identify missense mutations at R882 
and at 3 other amino acid positions in 23 of 112 (20.5%) patients with AML-M5 [79]. It 
is currently unclear whether some of these mutations (e.g., the highly recurrent R882 
mutations) might be associated with a gain of function. 
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In 2013, the Cancer Genome Atlas Research Network analyzed the genomes of 
200 clinically annotated adult cases of de novo AML, using either WGS (50 cases) or 
WES (150 cases), along with RNA and microRNA sequencing and DNA-methylation 
analysis. AML genomes have fewer mutations than most other adult cancers, with an 
average of only 13 mutations found in genes. Of these, averages of 5 are in genes that 
are recurrently mutated in AML. A total of 23 genes were significantly mutated, and 
another 237 were mutated in two or more samples. Nearly all samples had at least 1 
nonsynonymous mutation in one of nine categories of genes that are almost certainly 
relevant for pathogenesis, including transcription-factor fusions (18% of cases), the 
gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%), DNA-
methylation-related genes (44%), signaling genes (59%), chromatin-modifying genes 
(30%), myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and 
spliceosome-complex genes (14%). Patterns of cooperation and mutual exclusivity 
suggested strong biologic relationships among several of the genes and categories. 
Their study identified at least one potential driver mutation in nearly all AML samples 
and found that a complex interplay of genetic events contributes to AML pathogenesis 
in individual patients [85]. 
Regarding others myeloid disorders, in 2011, Bejar et. al. [86] used a 
combination of genomic approaches, including NGS and mass spectrometry-based 
genotyping, to identify mutations in samples of BM aspirate from 439 patients 
with MDS. They identified somatic mutations in 18 genes, including two, ETV6 and 
GNAS that have not been reported to be mutated in patients with MDS. A total of 51% 
of all patients had at least one point mutation, including 52% of the patients with 
normal cytogenetics. Mutations in RUNX1, TP53, and NRAS were most strongly 
associated with severe thrombocytopenia and an increased proportion of BM blasts. In 
a multivariable Cox regression model, the presence of mutations in five genes retained 
independent prognostic significance: TP53, EZH2, ETV6, RUNX1 and ASXL1.  
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CHAPTER 2: Aims 
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The Human Genome Project and the advances in sequencing technologies have 
revolutionized our ability to characterize cancers at the molecular level. Using next-
generation sequencing (NGS), it is now possible to interrogate cancers genome wide at 
a single-base-pair resolution. Application of NGS to myeloid leukemia has already 
yielded important discoveries, including the identification of common gene mutations 
(eg, IDH1 and DNTM3A). However, these efforts have so far excluded rare myeloid 
disorders. Taking all this into account, we proposed the next aims:  
1. Evaluate if a systematic genomic strategy based on whole-genome sequencing, 
RNA sequencing and target re-sequencing approaches could provide a deeper 
insights into the genetic pathogenesis of rare myeloid disorders.  
2. If so, to evaluate how these technologies can be used to improve the clinical 
management of the affected patients. In detail: 
2.1 In a rare case of blastic transformation of chronic myeloid leukemia 
• Identify the genetic changes associated with this transformation by whole-
exome sequencing 
• Study additional alterations in malignant cells (Ph+), related with no 
response to therapy, and their frequency in a validation cohort 
2.2 In a case of chronic neutrophilic leukemia (CNL) 
• Identify the genetic changes associated with CNL pathogenesis by whole-
exome sequencing 
• Identify the CNL transcriptome profiling and determine the functional 
consequences of LUC7L2 and U2AF1 mutations in splicing by RNA 
sequencing 
2.3 In a series of patients with blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) 
• Identify the genetic changes associated with BPDCN pathogenesis by whole-
exome sequencing 
• Design  a comprehensive and cost-effective target re-sequencing approach 
based on the WES results and study the frequency of mutations in a 
validation cohort 
• Evaluate the impact of mutation in the patients outcome  
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and Methods 
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3.1 Patients samples 
All patients samples included in this work fulfilled the 2008 WHO classification 
criteria for myeloid neoplasm [21]. A proper inform consent was obtained from each 
patient and the study was approved by the ethical research and animal care 
committee from Institute of Health Carlos III (CEi PI 32_2009). 
Data collection comprised the following clinical and analytical parameters: birth 
date, gender, hospital of origin, diagnosis date, histological subtype, extra medullary 
affection, stage, hemoglobin, white blood cell count, lymphopenia (lymphocytes <600), 
leukocytosis (leucocytes > 15000), IPS, treatment, type of response (CR: complete 
response; PR: partial response; P: progression) and data regarding last follow up (dead, 
alive with or without disease). 
The sample came from 10 clinical and basic research groups in Spain:  Hospital 
La Paz (Madrid), Complejo Hospitalario Ntra. Sra. de Candelaria (Sta. Cruz de Tenerife), 
Hospital General Universitario Gregorio Marañón (Madrid), Hospital Universitario La Fe 
(Valencia), Hospital Universitario Marqués de Valdecilla (Santander), Hospital 
Universitario de Salamanca (Salamanca), Hospital Universitario 12 de octubre 
(Madrid), Universidad de Navarra (Pamplona), Hospital del Mar (Barcelona) and  
Hospital Niño Jesus (Madrid).  
Different patient series were used in this work and considered as follows: 
3.1.1 Chronic Myeloid Leukemia (CML) project 
Samples were obtained from normal tissue (oral mucosa) and tumor bone 
marrow (BM) blasts at three different time-points (CP, complete hematological 
remission-CHR and BC) of a index patient with CML. These samples were used as a 
discorevy cohort to identify the genetic changes associated with transformation to the 
aggressive phenotype of blastic crisis by whole-exome sequencing (WES). The 
candidate mutations were analyzed in 26 additional CML samples: 13 at CP-CML paired 
with 13 follow up/ BC- CML (extension cohort). A summary of the clinical 
characteristics of CML patients can be found in Table 9 and in the chapter 4.1.1 of this 
thesis. 
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3.1.2 Chronic Neutrophilic Leukemia (CNL) project 
Samples were obtained from normal tissue and BM of an index patient with 
CNL before treatment. The detailed clinical characteristic of this patient is described in 
chapter 4.2.1 of this thesis. After cytogenetic and molecular studies for diagnosis 
purpose, these samples were used for WES and RNA sequencing studies. 
3.1.3 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) project 
 Samples for WES were obtained from normal tissue and tumor BM from three 
patients with BPDCN (discovery cohort) at diagnosis. Thirty-nine additional tumors 
were further included for the targeted re-sequencing analysis: 11 tumor samples came 
from BM cells, and 28 samples from formalin fixed paraffin embedded tissues (FFPE) 
(extension cohort). Clinical characteristics of the patients are summarized in Table 4. 
3.2 Molecular cytogenetics  
Cytogenetic analysis was performed on metaphases spreads obtained from the 
BM sample, as previously described [87]. The chromosomes were stained using the G-
banding technique and 20 metaphases were analyzed using a conventional microscope 
and the IKAROS-software (Metasystems). Clonal chromosomal abnormalities were 
described according to the International System of Human Cytogenetic Nomenclature 
(ISCN, 2013).  
Metaphase spreads obtained from the patient were hybridized overnight at 
37°C with commercial diagnosis probes. Following post-hybridization washes, the 
chromosomes were counterstained with DAPI in antifade solution (Vector Labs). Cell 
images were captured using a CCD camera (Photometrics SenSys camera) connected to 
a computer running the Chromofluor image analysis system (Cytovision, Applied 
Imaging Ltd, Newcastle, UK). 
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ID Sample Site Age (years) Sex CD4 CD56 CD123 TCL1 CD19 CD3 CD33 Skin Bone Marrow Peripheral Blood Lymph node Other sites Treatment
1* D BM 66 M  +  +  +  - NA NA  + n y n n n Dasatinib
2* D BM 68 M  +  +  + NA NA NA  + y y n n n AML-like
3* D BM 31 F  + NA NA NA NA NA  + y y n n n AML-like
4 D BM 14 M  +  +  + NA  -  -  + y y y y y ALL/Lymphoma-like
5 D BM 56 M  +  +  + NA  -  -  + n y y n n AML-like
6 D BM 71 M  +  + NA NA  -  -  + y y y n n ALL/Lymphoma-like
7 D BM 57 M  +  +  + NA  -  -  - n y y y y ALL/Lymphoma-like
8 D BM 64 M  +  -  + NA  -  -  - y y y y y ALL/Lymphoma-like
9 D BM 63 F  +  -  + NA  -  -  - y y y n n None
10 D BM 28 F  +  +  + NA  -  -  - y y n n y ALL/Lymphoma-like
11 D BM 39 F NA  -  + NA  - NA  + n y y n n AML-like
12 D BM 41 F  +  -  + NA  -  -  - n y y y n ALL/Lymphoma-like
13 D BM 35 M  +  -  + NA  -  -  - y y y n n ALL/Lymphoma-like
14 D SP 74 M  +  +  + NA  -  -  - y y y y y None
15 D BM 69 M  +  +  +  + NA  - NA y y NA n n ALL/Lymphoma-like
16 D NA NA NA  +  +  +  + NA  - NA NA y NA NA NA NA
17 D S 62 M  +  +  +  + NA  - NA y y NA y y AML-like
18 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
19 D S 65 M  +  +  +  + NA  - NA y y NA y y ALL/Lymphoma-like
20 D BM 29 F  +  +  +  + NA  - NA NA y NA n y ALL/Lymphoma-like
21 D S 12 F  +  +  +  + NA  - NA y n NA y n ALL/Lymphoma-like
22 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
23 D S 76 M  +  +  +  + NA  - NA y n NA y n None
24 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
25 D S 59 M  +  +  +  + NA  - NA y y NA y NA ALL/Lymphoma-like
26 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
27 D Ly NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
28 D S 43 F  +  +  +  + NA  - NA y n NA y n ALL/Lymphoma-like
29 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
30 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
31 D S 79 M  +  +  +  + NA  - NA y y NA n n ALL/Lymphoma-like/ AML-like
32 D S 45 F  +  +  +  + NA  - NA NA NA NA y y ALL/Lymphoma-like
33 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
34 D S 79 M  +  +  +  + NA  - NA y n NA n n ALL/Lymphoma-like
35 D S 61 M  +  +  +  + NA  - NA y y NA y y ALL/Lymphoma-like
36 D S NA NA  +  +  +  + NA  - NA NA y NA y NA NA
37 D Ly 7 M  +  +  +  + NA  - NA y n NA y n ALL/Lymphoma-like
38 D S 80 M  +  +  +  + NA  - NA y y NA n NA ALL/Lymphoma-like
39 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
40 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
41 D S NA NA  +  +  +  + NA  - NA NA NA NA NA NA NA
42 D S 13 F  +  +  +  + NA  - NA y n NA n n ALL/Lymphoma-like
*Whole-exome sequencing; BM: bone marrow; S: skin; Ly: lymph node; PB: peripheral blood;  D: diagnosis; CR: complete remission; R: relapse; BPDCN: blastic plasmocitoid dendritic cell neoplasm; M: male; F: female; NA: not available; y: yes; n: no; NoR: no response
Tumour Phenotype Sites of involvement at Diagnosis
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3.3 Whole-Exome Sequencing (WES)  
DNA was extracted by a phenol–chloroform standard method and the quality 
and quantity of purified DNA was assessed by fluorometry (Qubit, Invitrogen) and gel 
electrophoresis. 
The preparation of shotgun libraries from the leukemic and non-leukemic 
genomic DNA followed the “SureSelect Human All Exon Kit” protocol (Agilent 
Technologies, Santa Clara, CA), covering 50 Mb of coding exons (approximately 1.60% 
of the genome). Briefly, 1–3 µg of high molecular weight genomic DNA from each 
sample was fragmented by acoustic shearing on a Covaris S2 instrument. Fractions of 
150–300 bp were ligated to Illumina adapters and PCR-amplified for 6 cycles. Exon 
Enrichment: 300 ng of whole library were hybridized to SureSelect Human All Exon 
Capture kit for 24 h at 65ºC. Biotinylated hybrids were captured, and the enriched 
libraries were completed with 12 cycles of PCR. The resulting purified DNA library was 
applied to an Illumina flow cell for cluster generation and sequenced using the Illumina 
Genome Analyzer IIx for 76 bases in a paired-end format by following the 
manufacturer protocols.  
3.4 WES bioinformatic analysis 
The bioinformatics analysis began from the sequencing raw data (.fastq files) 
which generated from the Illumina pipeline. Sequenced reads were quality-checked 
with FastQC [88]. First, the adapter sequence in the raw data was removed, and low 
quality reads which have too many Ns and low base quality bases were discarded. This 
step produced the “clean data”. Second, a combination of Burrows-Wheeler Aligner 
(BWA) and Blat-like Fast Accurate Search Tool (BFAST) were used to do the short-reads 
alignment.  For the mapping we use the human genome build37 (hg19) as the 
reference genome. BWA+BFAST provide alignments in BAM format. Base qualities 
were recalibrated using the Genome Analysis Tool Kit (GATK) v1.03540 
(http://www.broadinstitute.org/gsa/wiki/ index.php/The_Genome_Analysis_Toolkit) 
and duplicate fragments marked using Picard Tools v1.17 
(http://picard.sourceforge.net/).  After these processes, the final BAM files used to do 
the variant calling got ready. The BAM files were also used to visualize aligned reads 
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using IGV (Integrative Genomics Viewer) program 
(http://www.broadinstitute.org/igv/). We used GATK library to detect Single 
Nucleotide Polymorphisms (SNPs) and to annotate the confident variant results. The 
resulting call sets in the target regions (50Mb) with a sequence read depth of ≥ 10x 
were reported.  The final variants can feed to the downstream advanced analysis 
pipeline. The SNP Effect Predictor tool was used to quickly and accurately predict the 
effects of variants on Ensembl-annotated transcripts 
(http://www.ensembl.org/Homo_sapiens/UserData/UploadVariations) [89]. 
We selected the single nucleotide variations (SNVs) and small insertions and 
deletions (indels) filtered them by discarding (i) variants present in the sequenced 
matched normal cells of the patient or in the dbSNP132 database and (ii) variants in 
intergenic or intronic regions. Next, we selected only those variants within coding 
regions not predicted to produce synonymous amino acid changes and presenting 
sufficient depth and quality. After that, we checked candidate variants against the 
1000 Genomes Project data. The percentage of reads supporting the mutation of the 
total number of reads at a given position was taken as >15% in the tumor DNA, and 
0.5% in normal DNA [90]. Data has been deposited in the Sequence Read Archive (SRA) 
database. In order to estimate the functional consequences of the missense mutations, 
we used two different algorithms: SIFT and PolyPhen-2. 
Figure 4 represents a workflow scheme form WES procedure and bioinformatic 
analysis. 
3.5 Ingenuity Pathway Analysis (IPA) 
Genes found to be mutated among the cases were subjected to Ingenuity 
Pathways Analysis (IPA) (Ingenuity Systems) and used as a starting point for building 
biological networks (http://www.ingenuity.com/products/ipa). IPA uses the proteins 
from the highest-scoring network to extract a connectivity pathway that relates 
candidate proteins to each other based on their interactions. The involved Function ＆ 
Disease and Canonical Pathways were shown to be significantly associated with these 
candidates.  
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Figure 4: Workflow scheme for exon enrichment and WES analysis. After alignment of the sequencing 
reads from DNA samples of tumor and normal cells to the human reference genome, a series of filters 
were applied to discard reads that were not usable for the downstream purpose of somatic mutation 
discovery. Sequence variants fulfilling the additional criteria were subjected to Sanger sequencing 
validation. 
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3.6 Targeted Re-Sequencing 
We design a custom panel of 38 genes (Table 5) using SureDesign Tool 
(https://earray.chem.agilent.com/suredesign/), which are prone to harbor mutations 
involved in leukemogenesis (n=25) and have been identified in our WES previous 
analysis (n=13). This panel is composed of genes from nine categories: DNA 
methylation (5 genes), chromatin remodeling (4 genes), transcription factors (10 
genes), splicing (5 genes), protein kinase (6 genes), ubiquitination (4 genes) and three 
additional singular genes (9 categories) .Ion semiconductor sequencing on the Ion 
Torrent Personal Genome Machine (PGM) was performed using the HaloPlex PCR 
target enrichment system (Halo Genomics, Uppsala, Sweden). In short, patient DNAs 
were digested by a cocktail of restriction enzymes and hybridized to specific probes 
incorporating Ion Torrent specific sequence motifs. Hybridized molecules were 
captured with magnetic beads, subsequently amplified using indexed primers (Ion One 
Touch Template Kit), and finally sequenced with the Ion Sequencing Kit v2.0 on an Ion 
316 chip. Data were analyzed with Variant Caller v2.2.3-31149 (all Life Technologies, 
Carlsbad, CA). 
3.7 Sanger sequencing validation and screening 
We used polymerase chain reaction (PCR) amplification and direct DNA 
sequencing to validate candidate variants. Because of the sensitivity of Sanger, 
sequence variants that were reported in less than 20% of the reads could not be 
included in this validation phase. The purified products were subsequently sequenced 
using the automatic sequencer ABI 3730xl (PE Applied Biosystems, Foster City, CA). 
Data were analyzed with BioEdit Sequence Alignment Editor 7.0.5.3. Sequences of 
primers used are listed on chapter 4 of this thesis according to each project. 
PCR and direct DNA Sanger sequencing of IKZF3, ASXL1 and TP53 were 
performed in 13 paired diagnosis and follow-up/BC samples. Primers spanning all 
coding exons of IKZF3 (ENST00000346872), exon 13 of ASXL1 (ENST00000375687) and 
all coding exons of TP53 (ENST00000269305) are reported in Tables 6. 
Additionally, FLT3-ITD detection was carried out by conventional PCR in all 
samples as previously reported [91]. 
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3.8 RNA Sequencing (RNA seq)  
Total RNA was extracted from BM leukemia cells and from CD34+ cells (normal 
control) by TRIzol (Life Technologies, Carlsbad, CA), following the manufacturers 
protocol; 250-1000 ng of total RNA were used for the synthesis of cDNA libraries with 
TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA) according to the 
manufacturers recommendations. Sequencing by synthesis was performed on 
HiScanSQ sequencer (Illumina) at 75bp in paired end. 
3.9 RNA seq bioinformatics analysis 
Sequenced reads were quality-checked with FastQC [88]. The 75-nt paired-end 
reads were aligned to the human genome (GRCh37/hg19) with TopHat-2.0.4 [92] 
(using Bowtie 0.12.7 [93] and Samtools 0.1.16 [94]), allowing two mismatches and five 
multihits. Fusion transcripts were obtained with TopHat-Fusion [95]. 
Transcripts differential expression between samples was calculated with 
Cuffdiff (Cufflinks 1.3.0) [92], using the human genome annotation data set 
Homo_sapiens.GRCh37.65 from Ensembl. 
3.10  Real-time PCR validation 
LUC7L2 expression was validate by quantitative real-time RT-PCR starting from 
total RNA from the patient sample, which was reverse-transcribed using random 
hexamer primers with the TaqMan® Gold RT-PCR Kit (Hs00255388_m1 - Applied 
Biosystems, Foster City, CA). The Calibrated Normalized Relative Quantity, taking into 
account target- and run-specific amplification efficiencies, was calculated using 
endogenous GAPDH expression with the Qbase software application. PIM3-SCO2 
fusion transcripts were amplified (PIM3-2F: CGCGACATTAAGGACGAAAA /  SCO2-2R: 
GCCCTGCCTTGACAAAAG) and sequenced with BigDye terminator v3.1 Cycle 
Sequencing kit (PE Applied Biosystems, Foster City, CA) on an Applied Biosystems 310 
analyzer. 
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Table 5: Genes included in the target next generation sequencing 
N= Gene Coverage Source
1 ASXL1 100.0% CCDS13201.1
2 ATRX 100.0% CCDS14435.1, CCDS14434.1
3 CBL 100.0% CCDS8418.1
4 CBLB 100.0% CCDS2948.1
5 CBLC 100.0% CCDS12643.1, CCDS46109.1
6 CEBPA 100.0% CCDS54243.1
7 DNMT3A 100.0% CCDS1718.2, CCDS33157.1, CCDS46232.1
8 ETV6 100.0% CCDS8643.1
9 EZH2 96.4% CCDS5892.1, CCDS5891.1
10 FLT3 100.0% CCDS31953.1
11 HOXA1 100.0% CCDS5401.1, CCDS5402.2
12 HOXB9 100.0% CCDS11534.1
13 IDH1 100.0% CCDS2381.1
14 IDH2 100.0% CCDS10359.1
15 IKZF1 100.0% NM_001220773, NM_001220767
16 IKZF2 100.0% CCDS2395.1, CCDS46507.1
17 IKZF3 100.0% CCDS11346.1, CCDS11351.1, CCDS11349.1
18 JAK2 100.0% CCDS6457.1
19 KDM6A 100.0% CCDS14265.1
20 KIT 100.0% CCDS3496.1, CCDS47058.1
21 KRAS 100.0% CCDS8702.1, CCDS8703.1
22 LUC7L2 100.0% CCDS43656.1
23 MPL 100.0% CCDS483.1
24 NBL1 100.0% CCDS41278.1, CCDS196.1
25 NPM1 100.0% CCDS4376.1, CCDS43399.1, CCDS4377.1
26 NRAS 100.0% CCDS877.1
27 PDGFRA 100.0% CCDS3495.1
28 RUNX1 99.9% NM_001001890, NM_001754, NM_001122607
29 SF3B1 99.9% CCDS33356.1, CCDS46479.1
30 SRSF2 100.0% CCDS11749.1
31 TET1 100.0% CCDS7281.1
32 TET2 100.0% CCDS47120.1, CCDS3666.1
33 TP53 100.0% CCDS11118.1, CCDS45605.1, CCDS45606.1
34 U2AF1 100.0% CCDS33574.1, CCDS13694.1, CCDS42948.1
35 UBE2G2 98.2% CCDS33586.1, CCDS13714.1
36 WT1 100.0% CCDS44562.1, CCDS7878.2, CCDS44561.1
37 ZEB2 100.0% CCDS54403.1, CCDS2186.1
38 ZRSR2 97.5% CCDS14172.1
Number of target region: 469
Total target region size: 86266 bp
Coverage: 99,9% (86137 bp)  
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Table 6: Primers for ASXL1, IKZF3 and TP53 screening 
Primer name Sequence (5'-3')
ASXL1-13F GGACCCTCGCAGACATTAAA
ASXL1-13R AGCTCTGGACATGGCAGTTC
ASXL1-13aF GGTCAGATCACCCAGTCAGTT
ASXL1-13aR CACCACCATCACCACTGCT
ASXL1-13bF CAACTACTGCCGCCTTATCC
ASXL1-13bR GTCGGTGAGGATTCAGGTGT
ASXL1-13cF TGAAGGATCCTGTAAATGTGACC
ASXL1-13cR ATTGCTGTCACTGCCTCCTC
ASXL1-13dF TCACTCTGGACTGTGCCATC
ASXL1-13dR GCAGCAACTGCATCACAAGT
ASXL1-13eF CTCAGTGGAGGCCACTAACC
ASXL1-13eR CATAGCACGGACTTCCTTCTG
ASXL1-13fF CAGAAGGAAGTCCGTGCTATG
ASXL1-13fR GGGACTATGCCCAGTAGCTTT
ASXL1-13gF GGGTCCTCTTAAGGCAAATG
ASXL1-13gR GTTTCCCATGGCCATAATTT
IKZF3-2F GCTGTTAAGTTTTCCGAAATGG
IKZF3-2R AAGCACATTCCTCTCTCTTTGG
IKZF3-3F TGTGTGAAGCTGAAAGTTAAATGG
IKZF3-3R CTACAATTGCAAGTTTTCCTTGG
IKZF3-4F TCGTTGTTCATTTCTTGCATTT
IKZF3-4R TTCTCACGTGGCTGCATTAG
IKZF3-5F GAGCTTTTCCCCTAGGCATC
IKZF3-5R ACACTGGGCTCTGAGGAATG
IKZF3-6F AGTTGTCACAGAGCCCCAAT
IKZF3-6R ATCTGTCTGCCCCCAGTAAA
IKZF3-7F GCATCCAACTTCGGACACTT
IKZF3-7R TTTAACAGAGGTTAAGCTAGGAAAGG
IKZF3-8F CTTGGCAGTGTTCCCTTTGT
IKZF3-8R GGCGAGGTCATTGGTTTTTA
TP53-2-3F CCATTCTTTTCCTGCTCCAC
TP53-2-3R TCAAATCATCCATTGCTTGG
TP53-4F CCTGGTCCTCTGACTGCTCT
TP53-4R GACAGGAAGCCAAAGGGTGA
TP53-5F GTTTCTTTGCTGCCGTCTTC
TP53-5R GAGCAATCAGTGAGGAATCAGA
TP53-6F CTGCTCAGATAGCGATGGTG
TP53-6R TTGCACATCTCATGGGGTTA
TP53-7F GCACTGGCCTCATCTTGG
TP53-7R GGGATGTGATGAGAGGTGGA
TP53-8F TCTGGCTTTGGGACCTCTTA
TP53-8R GGAAAGAGGCAAGGAAAGGT
TP53-9F AAGCAAGCAGGACAAGAAGC
TP53-9R TGTCTTTGAGGCATCACTGC
TP53-10F AACTTGAACCATCTTTTAACTCAGG
TP53-10R GAAGGCAGGATGAGAATGGA
TP53-11F AAAGCATTGGTCAGGGAAAA
TP53-11R GCAAGCAAGGGTTCAAAGAC  
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3.11 Statistical analysis 
Overall survival (OS) was calculated taking into account the first date of 
diagnosis of BPDCN to death of disease or to last follow-up. Kaplan-Meier method was 
used to estimate the distribution of OS and differences in survival between groups 
were assessed using the log rank test with the SPSS v.19 software (SPSS Inc, Chicago, 
IL, USA). A P value of ≤.05 was considered statistically significant. 
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4.1 Part I: Whole-exome sequencing of chronic myeloid 
leukemia progression 
The mechanisms of transformation from chronic-phase (CP) to blast-crisis (BC) 
of chronic myeloid leukemia (CML) are heterogeneous and poorly understood [96]. The 
most frequently observed genetic aberrations at this advanced stage include a second 
Philadelphia chromosome (Ph), trisomy 8, isochromosome 17, and trisomy 19, alone or 
in various combinations [97]. Clonal cytogenetic evolution appears to be the most 
consitent predictor of blastic transformation, present in up to 80% of patients [98].  
At present, little is known about the mutational profiling of the different steps 
of CML progression. High- throughput genomic studies have been partially reported 
and only few mutations present at BC have been described [99]. The most common 
mutations in myeloid BC involve TP53 and RUNX1, found in about 25% and 40% of the 
cases, respectively [100, 101]. In lymphoid BC, the most commonly reported mutations 
involve CDKN2A [102], IKZF1 [103] and RB1 [104] in 50%, 55% and 20% of cases, 
respectively. In addition, clinical data indicate that development of ABL1 mutations 
during treatment and/or disease progression are associated with a poorer outcome 
[105-108].  
Although these findings have identified mutations at single time-points, the 
genomic basis of the progression of CML over time from diagnosis to end-stage disease 
remains unclear. Here, we used whole-exome sequencing (WES) to analyse the exome 
of one individual at three different time-points of CML progression. We also included 
additional patient samples to explore and define the incidence and recurrence of some 
mutations found in CP and BC. This approach allowed us to identify, even in the CP 
phase, mutations with prognostic and predictive significance as well as alterations that 
have not been described so far in this disease. 
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4.1.1 Case report 
The patient was a 65-year-old men diagnosed with a Ph+ CML and presented 
with a hypercellular bone marrow containing 2% blast cells. Karyotype analysis showed 
the Ph chromosome in all analyzed metaphases at diagnosis. The patient was treated 
with Imatinib® (400 mg/day) achieving, along the treatment,  complete hematological 
response after one month and complete cytogenetic response after 12 months. 
Conversely, he never achieved major molecular response during this period. 
Unfortunately, after 14 months from diagnosis the patient progressed to a myeloid 
blast crisis that did not respond to a 2nd line treatment (Dasatinib® + Idarubicin-AraC) 
and the patient died of the disease 18 months after diagnosis. At that time, the G-
banding analysis showed a complex karyotype (Figure 5).  
4.1.2 Identification of candidate somatic mutations in CML progression 
To identify somatic mutations during CML progression, we performed an 
exome sequencing of this index patient at three different phases of the disease: 
chronic phase (CP), complete cytogenetic response (CCyR) and in disease progression 
(blast crisis, BC). The preparation of shotgun libraries from the leukemic (CP, CCyR and 
BC) and non-leukemic genomic DNA obtained from the patient, followed by in-solution 
exome capture, was performed with the use of a commercial platform (Agilent) 
covering 50 Mb of coding exons (approximately 1.60% of the genome). After massively 
parallel sequencing with the Genome Analyzer IIx (Illumina), candidate somatic 
mutations were identified using the pipeline detailed at Material and Methods chapter 
of this thesis (pg.34). 
After discarding the variants present in the matched normal DNA and in the 
dbSNP132 database, we obtained a total of 3123, 7678 and 3306 single nucleotide 
substitutions (SNSs) and small insertions and deletions (indels) for CP, CCyR and BC, 
respectively. Next, we selected only those variants within coding regions that, passing 
depth and quality controls, were frameshift, stop gain/loss and non-synonymous 
amino acid changes predicted to produce deleterious damage in the protein structure. 
Finally, this resulted in 13, 7 and 15 SNSs/indels for CP, CCyR and BC, respectively, 
affecting a total of 20 genes (Table 7 and Figure 6A).  
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Figure 5: Karyotype during CML progression (A) chronic phase: 45, XY, t(9;22)(q34;q11.2), 
rob(13;14)(q10;q10) [20]; (B) complete cytogenetic response: 45, XY, rob(13;14)(q10;q10) [20]; and (C) 
blast crisis: 44, XY, t(9;22)(q34;q11.2), rob(13;14)(q10;q10), -17 [5]; 45, XY, t(9;22)(q34;q11.2), +10,  
rob(13;14)(q10;q10), -17 [5];  46, XY, t(9;22)(q34;q11.2), +8, +10,  rob(13;14)(q10;q10), -17 [3]; 47, XY, 
t(9;22)(q34;q11.2), +8, +10,  rob(13;14)(q10;q10), -17, +19 [2]; 45, XY, rob(13;14)(q10;q10) [5]. The blue 
arrows indicate the t(9;22) and the blue circles, the additional chromosome alterations. 
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Table 7: SNSs/indels  filtering steps of CML WES 
Filter CP CCyR BC 
Total 3123 7678 3306 
Somatic 719 1839 869 
Exonic 372 878 412 
Consequence* 77 81 66 
Quality Control 13 7 15 
*Frameshift, stop gain and non-synonymous-deleterious 
 
 
Among those SNSs and indels, we selected the variants present with a  
frequency higher than 20%, due to the limitations of Sanger sequencing (Table 8). We 
validated mutations in genes known to be involved in CML (such as ASXL1 and TP53) 
[109, 110] as well as in genes that have not been described so far in this disease, such 
as UBE2G2, ZEB2 and IKZF3 (Figure 6B). 
Interestingly, TP53 mutation (p.G244S) is present in all the stages which lead to 
suggest its potential role as a tumor-initiating events. On the other hand, ASXL1 
(p.G679*), UBE2G2 (p.D35V), ZEB2 (p.L420R) and IKZF3 (p.E272K) were present in both 
CP and BC, also suggesting that these alterations are initiating events and co-occur 
with BCR-ABL1 fusion gene (Figure 6A). All theses SNSs were validated using 
polymerase-chain-reaction (PCR) amplification and direct DNA sequencing of the same 
samples that were subjected to WES. Finally, we also found SNSs unique to the BC 
sample (ARSD and AADACL3 mutations) that may, therefore, contribute to leukemic 
transformation. However, we were not able to validate these two mutations probably 
due to Sanger sequencing limitations.  
Among the genes previously reported in CML progression [99, 111-114], we 
detected ASXL1 and TP53 mutations. Interestingly, TP53 mutation (p.G244S) was found 
in the three phases of CML progression and is present in the Catalogue of Somatic 
Mutations In Cancer (COSMIC) database [115]. There are some controversial results 
regarding its role in blastic transformation. Whereas some authors have observed 
mutations in 25%-30% of BC [97], a recent work by Grossman et al. [99], in which deep 
sequencing approach was used, they found a TP53 mutation only in one out of 39 
(2,6%) BC patients analyzed. 
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Figure 6: Mutational profile by whole exome sequencing along the three phases of CML. (A) Venn 
diagram representing the distribution of mutated genes distribution in CML progression; (B) Frequencies 
of the mutant alleles of every affected gene at the three time-points of CML progression. Sanger 
validation was conducted for those genes with frequencies above 20%: ZEB2, UBE2G2, TP53, TMEM57, 
IKZF3, C4BPA, ASXL1 and ADAMTS16. 
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CML-Phase Position Gene Name QUAL Coverage Freq_Var(%) Consequence DNA Level (cDNA) Protein Level PolyPhen SIFT
CP 5_33549323_G/T ADAMTS12 503,94 24 8 NON_SYNONYMOUS_CODING NM_030955.2:c.4291C>A p.Pro1431Thr probably_damaging tolerated
CP 5_5232589_G/A ADAMTS16 1206,77 96 50 NON_SYNONYMOUS_CODING NM_139056.2:c.1810G>A p.Gly604Arg probably_damaging deleterious
CP 20_31022550_G/T ASXL1 323,4 27 48 STOP_GAINED NM_015338.5:c.2035G>T p.Gly679* NA NA
CP 1_207305072_C/G C4BPA 1060,02 57 61 STOP_GAINED NM_000715.3:c.1071C>G p.Tyr357* NA NA
CP 4_1388623_-/CA CRIPAK 488,27 122 9 FRAMESHIFT_CODING NM_175918.3:c.324_325insCA p.Thr109Glnfs*82 NA NA
CP 2_71801335_-/AGGCGG DYSF 320,44 24 20 FRAMESHIFT_CODING NM_001130987.1:c.3236delinsAGGCGG p.Glu1081Glyfs*59 NA NA
CP 17_37922621_C/T IKZF3 707,81 50 48 NON_SYNONYMOUS_CODING NM_012481.3:c.952G>A p.Glu318Lys probably_damaging deleterious
CP 4_23825925_23825926delinsCT PPARGC1A 999,13 113 35 NON_SYNONYMOUS_CODING NM_013261.3:c.854_855delinsAG p.Ser285Lys probably_damaging deleterious
CP 1_25824890_A/G TMEM57 2076,54 155 50 NON_SYNONYMOUS_CODING NM_018202.4:c.1928A>G p.Lys643Arg probably_damaging tolerated
CP 17_7577551_C/T TP53 768,45 47 62 NON_SYNONYMOUS_CODING NM_000546.4:c.730G>A p.Gly244Ser probably_damaging deleterious
CP 15_41870343_C/T TYRO3 244,25 23 4 NON_SYNONYMOUS_CODING NM_006293.3:c.2542C>T p.Arg848Trp probably_damaging deleterious
CP 21_46197270_T/A UBE2G2 1222,13 87 52 NON_SYNONYMOUS_CODING NM_003343.5:c.188A>T p.Asp63Val probably_damaging deleterious
CP 2_145157495_A/C ZEB2 954,8 67 55 NON_SYNONYMOUS_CODING NM_014795.3:c.1259T>G p.Leu420Arg probably_damaging deleterious
CCyR 4_1388623_-/CA CRIPAK 427,91 141 9 FRAMESHIFT_CODING NM_175918.3:c.324_325insCA p.Thr109Glnfs*82 NA NA
CCyR 12_53207608_-/CAG KRT4 1437,89 198 5 IN-FRAME NM_002272.2:c.457_458insCAG p.Gly152_Gly153insAla NA NA
CCyR 22_29885623_-/AGGAAG NEFH 894,64 248 4 IN-FRAME NM_021076.3:c.1994_1995insAGGAAG p.Lys665_Ala666insGlyArg NA NA
CCyR 5_43613188_TGCCCAAATCCAA/- NNT 264,02 91 18 FRAMESHIFT_CODING NM_012343.3:c.330_342del p.Ala111Glyfs*23 NA NA
CCyR 13_25671311_TATGA/- PABPC3 225,27 197 9 FRAMESHIFT_CODING NM_030979.2:c.976_980del p.Met326Glyfs*21 NA NA
CCyR 13_21729832_-/TGGAATTT SKA3 1464,5 81 9 SPLICE_SITE,FRAMESHIFT_CODING NM_145061.5:c.1238_1238+1insTGGAATTT p.*413Cysfs*4 NA NA
CCyR 17_7577551_C/T TP53 250,69 45 27 NON_SYNONYMOUS_CODING NM_000546.4:c.730G>A p.Gly244Ser probably_damaging deleterious
BC 1_12785494_G/- AADACL3 575,54 187 5 FRAMESHIFT_CODING NM_001103170.1:c.584del p.Cys195Phefs*17 NA NA
BC 5_33549323_G/T ADAMTS12 633,95 46 50 NON_SYNONYMOUS_CODING NM_030955.2:c.4291C>A p.Pro1431Thr possibly_damagin tolerated
BC 5_5232589_G/A ADAMTS16 723,43 103 30 NON_SYNONYMOUS_CODING NM_139056.2:c.1810G>A p.Gly604Arg possibly_damagin deleterious
BC X_2835999_CCACGCCGG/- ARSD 278,35 29 17 IN-FRAME NM_001669.2:c.701_709del p.Ala234_Val236del NA NA
BC 20_31022550_G/T ASXL1 390,7 35 49 STOP_GAINED NM_015338.5:c.2035G>T p.Gly679* NA NA
BC 1_207305072_C/G C4BPA 511,16 53 36 STOP_GAINED NM_000715.3:c.1071C>G p.Tyr357* NA NA
BC 4_1388623_-/CA CRIPAK 501,39 95 14 FRAMESHIFT_CODING NM_175918.3:c.324_325insCA p.Thr109Glnfs*82 NA NA
BC 3_75714825_G/- FRG2C 294,25 243 20 FRAMESHIFT_CODING NM_001124759.1:c.483del p.Arg161Serfs*5 NA NA
BC 17_37922621_C/T IKZF3 618,13 57 39 NON_SYNONYMOUS_CODING NM_012481.3:c.952G>A p.Glu318Lys possibly_damagin deleterious
BC 4_23825925_23825926delinsCT PPARGC1A 1318,91 117 41 NON_SYNONYMOUS_CODING NM_013261.3:c.854_855delinsAG p.Ser285Lys possibly_damagin deleterious
BC 1_25824890_A/G TMEM57 1452,52 199 29 NON_SYNONYMOUS_CODING NM_018202.4:c.1928A>G p.Lys643Arg possibly_damagin tolerated
BC 17_7577551_C/T TP53 228,95 17 50 NON_SYNONYMOUS_CODING NM_000546.4:c.730G>A p.Gly244Ser possibly_damagin deleterious
BC 15_41870343_C/T TYRO3 142,13 38 20 NON_SYNONYMOUS_CODING NM_006293.3:c.2542C>T p.Arg848Trp possibly_damagin deleterious
BC 21_46197270_T/A UBE2G2 1439,23 104 50 NON_SYNONYMOUS_CODING NM_003343.5:c.188A>T p.Asp63Val possibly_damagin deleterious
BC 2_145157495_A/C ZEB2 808,39 69 45 NON_SYNONYMOUS_CODING NM_014795.3:c.1259T>G p.Leu420Arg possibly_damagin deleterious 
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4.1.3 Defining TP53, IKZF3 and ASXL1 mutation frequencies in CML 
diagnosis and progression 
Due to their biological and clinical relevance, we analyzed the TP53, ASXL1 and 
IKZF3 gene in an independent set of 26 samples consisting of 13 paired CML and 
BC/NCgR (no cytogenetics response) samples. No mutations in TP53 were found. 
Although it seems that mutations affecting TP53 gene can be considered as a rare 
event in the progression of CML, the presence of the mutation in all three phases 
confirm that it is clearly related to a non standard response to the treatment and/or 
clinical progression.  
Regarding ASXL1, mutations in this gene during CML evolution were described 
for the first time by Boultwood et al. [112]  They found mutation in six out of 41 
patients analyzed (3 CP and 3 BC non paired samples; 14,5%), however in the only BC 
sample for which CP paired sample had available, they did not detect the same 
mutation. Subsequently, other authors have observed ASXL1 mutations in similar 
frequencies [99, 116, 117] and among these earlier works, ASXL1 gene is the 
commonly affected gene. According with these previous findings, we detect a 
missense mutation in the patient sequenced and we also observed two different 
mutations in four out of 26 (15%) in BC/NCgR and also in the CP paired samples 
analyzed (Table 9). All these data together corroborate that ASXL1 mutations 
constitute an early event and might cooperate with other alteration such BCR-ABL1. 
Regarding mutations found in CP and BC, it is important to mention the 
mutation observed in IKZF3 (p.E272K). IKZF3 is a member of the Ikaros transcription 
factors family, which are important regulators of lymphoid differentiation. Among the 
five members of the family, IKZF1 have been found deleted and mutated in acute 
lymphoblastic leukemia (ALL), CML blastic phase and BCR-ABL1 positive ALL suggesting 
a pathogenetic contribution to leukemic transformation [118]. In addition, this genetic 
alteration have been found also in 19% of patients with blast-phase myeloproliferative 
neoplasm leading to suggest a potential pathogenic role in the myeloid lineage [119]. 
To date, mutations in other members apart from IKZF1 have never been described in 
human leukemia. In order to explore this genetic feature, we screened for mutation in 
IKZF3 gene in the 26 samples using conventional PCR and Sanger sequencing. IKZF3 
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were also mutated in 8% of CP and BC/NCgR samples, suggesting a potential role of 
this gene in myeloid leukemia (Table 9). 
4.1.4 Clonality assessment in CML progression 
The application of WES approach allowed determining the clonality and clonal 
evolution patterns during the CML progression. In this sense, 93% of the selected SNSs 
that were present in the CP were also seen in BC. In fact, the percentages of reads of 
the mutant alleles identified for the most relevant genes were the same (around 50%) 
both at CP and at BC (Fig.6B). As expected, these data suggest that the same clone was 
present in CP and BC. 
In summary, WES allowed the identification of a large number of mutated 
genes, even at the chronic phase of CML that harbor prognostic and predictive 
significance, such as ASXL1 and TP53, both found mutated at CP and BC. The study of 
the mutation profile through the course of the disease indicated that, at least in this 
patient, the number and the type of mutations were similar at CP and BC. In addition, 
we identified for the first time deleterious mutations in IKZF3, UBE2G2 and ZEB2 in 
CML at diagnosis. While current diagnostic procedures recommend the study of ABL1 
mutations in non-responders patients, our data suggest that sequencing a wider panel 
of genes could be also beneficial in the clinical management of these patients.  
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Age
 (years) ASXL1 IKZF3 TP53
CP 45,XY,t(9;22)(q34;q11.2),rob(13;14)(q10;q10)c[20] c.2035G>T c.952G>A c.730G>A
BC 44,XY,t(9;22)(q34;q11.2),rob(13;14)(q10;q10)c,-17 [19]/46,XY,t(9;22)(q34;q11.2),+10,rob(13;14)(q10;q10)c,-17[1] c.2035G>T c.952G>A c.730G>A
CP 46,XX,t(9;22)(q34;q11.2)[20] c.2498_2501del wt wt
NCgR 46,XX, t(9;22)(q34;q11.2)[20] c.2498_2501del wt wt
CP 46,XY,t(9;22)(q34;q11.2)[20] wt wt wt
NCgR 46,XY,t(9;22)(q34;q11.2)[6]/46,XY[14] wt wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
BC 47,X,-X,+der(1)t(1;?)(p12;?),-5,+6,+8,t(9;22)(q34;q11.2),-9,-14,-17,-18,+21,+der(22)t(9:22)(q34;q11.2),+1mar[cp2]/46,XX[6] wt wt wt
CP 46,XY,t(2;13)(p36;?),t(9;22)(q34;q11)[20] wt wt wt
NCgR 46,XY,t(2;13)(p36;?),t(9;22)(q34;q11)[1]/46,XY[19] wt wt wt
CP 46,XY,t(9;22)(q34;q11.2)[4]/46,XY,t(9;9;22)(p12;q34;q11.2)[10]/46,XY[6] wt wt wt
NCgR 46,XY[11]/46,XY,t(9;9;22)(p12;q34;q11.2)[5] wt wt wt
CP 46,XY,t(9;22)(q34;q11.2)[7]/46,XY[8] wt wt wt
NCgR 46,XY,t(9;22)(q34;q11.2)[2]/46,XY[18] wt wt wt
CP 46,XY,t(9;22)(q34;q11.2),der(3)t(3;?)(?;?)[7]/46,XY,t(9;22)(q34;q11.2)[8] wt c.71C>T wt
BC 46,XY,t(9;22)(q34;q11.2)[2]/46,XY[26] wt c.71C>T wt
CP 46,XY[3]/46,XY,t(9;22)(q34;q11.2)[17] c.2598A>G wt wt
BC 46,XY[2]/47,XY,+X,-7,der(9)i(9)(q34;q11.2),+mar[18] c.2598A>G wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
NCgR 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] c.1937dup wt wt
NCgR 46,XX,t(9;22)(q34;q11.2)[20] c.1937dup wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
BC 47,XX,t(9;22)(q34;q11.2),+t(9;22)(q34;q11.2)[10]/46,XX,t(9;22)(q34;q11.2)[8]/46,XX[2] wt wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
NCgR 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
CP 46,XX,t(9;22)(q34;q11.2)[20] wt wt wt
BC 45,XX,-7,t(9;22)(q34;q11.2)[8]/46,XX[12] wt wt wt
12 14
13 69/F 3
14 NA 24
60/F
10 44/F 24
11 73/F 20
8 34/M 12
9 8/M 4
6 85/M 7
7 36//M 58
4 41/F 5
5 54/M 5
2 31/F 6
3 70/M 3
Id Type Follow-up (months) Karyotype
Mutational status
1* 65/M 18
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4.2 Part II: Genomic characterization of chronic neutrophilic 
leukemia 
Chronic neutrophilic leukaemia (CNL) is a rare but distinct myeloproliferative 
neoplasm (MPN) characterized by the presence of leukocytosis, hypercellularity of bone 
marrow (BM), a sustained mature neutrophilia in peripheral blood (PB), 
hepatosplenomegaly, lack of detectable BCR-ABL1 transcripts, as well as by the 
absence of rearrangements in PDGFRA/B and FGFR1. According 2008 WHO 
classification, the diagnosis is based on the neoplastic expansion of granulocytic cells 
and the exclusions of genetic drivers that are known to occur in other MPN [21]. 
Recent studies identified the presence of CSF3R mutations in more than 50% of 
patients with CNL or atypical chronic myeloid leukemia (aCML). CSF3R encodes the 
trans-membrane receptor for granulocyte colony-stimulating factor (G-CSF; CSF3), 
which provides the proliferative and survival signal for granulocytes and also 
contributes to their differentiation and function [120].  The oncogenic CSF3R mutations 
are molecular markers of sensitivity to inhibitors of SRC family-TNK2 and JAK kinases 
and may provide a new avenue for therapy [38, 121]. 
However, no comprehensive massive next-generation sequencing study has 
been performed to explore the whole picture of the disease. Here we use whole-exome 
sequencing (WES) and RNA sequencing (RNA-seq) to look at additional genetic 
abnormality in CNL. In addition to the CSF3R p.Thr618Ile mutation, we were able to 
identify others mutations (on spliceosome, chromatin remodeling and methylation 
genes), loss of heterozygozity (LOH), splicing abnormalities and fusion genes that, 
together, could explain the complexity and aggressiveness of this disease. 
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4.2.1 Case Report 
A 66-year-old man was diagnosed with CNL, according to 2008 WHO 
classification. At presentation, the patient presented peripheral blood leukocytosis 
(66x109/L), segmentted neutrophils and band forms were 91.5% of the white blood 
cells counts (WBCs), immature granulocytes were <10% of WBCs and myeloblasts were 
<1%. The aspirate showed a hypercellular BM with neutrophilic granulocytes increased 
in number and a percentage and myeloblasts 0.5% of WBCs. No dysplastic features 
were observed in the myeloid lineages. His Zubrod Performance Status (ECOG) was 1. 
G-banding chromosome analysis revealed a normal karyotype (46,XY[20]) and 
molecular biology studies were negative for BCR-ABL1 transcripts and JAK2 V617F 
mutation. The patient was treated with hydroxyurea, but, unfortunately, died seven 
months after diagnosis due to an intensification of the disease. 
4.2.2 Mutations in coding sequencing by WES of CNL 
To improve our understanding of the genes involved in the pathogenesis of 
CNL, WES was performed on matched tumor and normal sample from the patient. 
Candidate somatic mutations were identified using RUbioSeq software [89]. The 
bioinformatics analysis and the filtering steps to identify the coding variants are 
detailed in the Material and Methods chapter of this thesis (pg.34). In total, we found 
1437 somatic mutations and, among them, 797 were intronic, intergenic, affecting 
non-conding-RNA or untranscribed regions. From the 640 exonic variants, we selected 
only those variants within coding regions that, after passing sequencing depth and 
quality filters were, frameshift, stop gain/loss and non-synonymous amino acid 
changes predicted to produce a deleterious effect in the protein structure.This process 
resulted identified a total of 24 SNSs/indels. In addition to the CSF3R p.Thr618Ile 
mutation, we found by WES sequencing mutations in: U2AF1, TET2, LUC7L2 and ASXL1 
(Figure 7 and Table 10). 
The current study has several focus of interest, firstly, it confirms the 
observations by Maxon et al. [38] and Pardanani et al [121], regarding the association 
between CNL and CSF3R mutations. Secondly, it presents a complete picture of the 
mutational profiling of CNL, certainly more complex than expected from these 
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previous reports. In fact, we found and validated mutations affecting both splicing 
machinery and epigenetic genes as mentioned. Kosmider et. al.  [122], very recently, 
showed that CSF3R somatic mutations can be identified in ~4% of chronic 
myelomonocytic leukemias. These mutations, which affect distinct residues in CSF3R as 
compared to CNL, are frequently associated with mutations in ASXL1 gene and have a 
poor prognostic impact on overall and acute myeloid leukemia (AML)-free survival. 
Taking into consideration these reported data, it seems that also the CNL genome 
displays a combination of few mutations with a pattern of cooperation with strong 
biologic relationship among genes and categories, being this scenario similar to the 
one observed in others myeloid disorders, such as AML [69]. In a very similar way to 
what happens in other myeloid disorders, this type of cooperating mutations in 
epigenetic genes was also found in our CNL patient, whose leukemic genome showed 
mutated copies of ASXL1 and TET2 genes. 
 
Figure 7: Mutational profiling of CNL. In addition to the CSF3R p.Thr618Ile mutation, WES revealed 
mutations in: U2AF1, TET2, LUC7L2 and ASXL1. LUC7L2 mutation was found in homozygosis. 
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Table 10: Description of validated mutations in the CNL patient 
Chrom Position  Gene Name Zygosity Ref Variant Var Freq Coverage AA change Type Provean SIFT
20 31024563 ASXL1 Het C T 46,12 2433 Q1350* Stop Gain NA NA
7 139060825 LUC7L2 Hom C T 96,55 261 R93* Stop Gain NA NA
4 106157539 TET2 Het CG C 23,81 126 NA Frameshift NA NA
21 44514777 U2AF1 Het T C 38,96 2477 Q157R Single AA Change Deleterious Damaging
1 36933434 CSF3R Het G A 43,23 1203 T618I Single AA Change Deleterious Damaging
NA: no aplicable; Het: heterozygotic; Hom: homozygotic; AA: aminoacid  
4.2.3 Loss of heterozygosity in 7q and detection of LUC7L2 expression 
The variant allelic frequency of LUC7L2 mutation was found to be high (more 
than 95%). Makishima et. al.  [123] previously described mutations of this gene in MDS 
and, since this gene is located in the 7q region, a frequently lost chromosomal region 
in myeloid leukemias [124], we decided to investigate whether a critical deletion or a 
loss of heterozygosity (LOH) affecting this genomic region was also present in the 
patient. To study this phenomenon, we interrogate our WES data for LOH across the 
genome of the sample. Interestingly, we found a LOH of 53.2MB in chromosome 7q 
including the locus of the LUC7L2 gene. Allele frequencies of each SNP along 
chromosome 7 are shown in Figure 8. Since no del(7q) was detected with metaphase 
cytogenetics, our study demonstrates for the first time mutations in LUC7L2 
accompanied by a copy-neutral LOH (uniparental disomy) in 7q in a patient with an 
aggressive CNL phenotype.  
 
Figure 8: 7q LOH in CNL. LOH of 53.2MB in chromosome 7q including the locus of LUC7L2 
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To evaluate the biological consequences of this homozygous mutation, we 
explored LUC7L2 expression in the bone marrow cells of the patient and in some 
myeloid leukemia cell lines (Figure 9). By real-time PCR, we observed a total abrogation 
of the expression of LUC7L2 in the patient cells as well as general down regulation in 
myeloid leukemia cell lines. This downregulation of LUC7L2 expression is a completely 
novel finding in the field and its biological and clinical consequences still remain to be 
further explored. 
 
Figure 9: LUC7L2 expression in CNL patient. Abrogation of LUC7L2 expression in CNL patient and down 
regulation in myeloid leukemia cell lines 
4.2.4 Effects of mutations in LUC7L2 and U2AF1 on spliceosomal function 
Conceptually, mutations of spliceosomal proteins, such as LUC7L2 and U2AF1, 
could result in defective splicing, including intron retention, altered splice site 
recognition, or altered alternative splicing. To determine the functional consequences 
of these mutations in the proper mRNA production and splicing process in CNL, we 
performed a complete and massive sequencing of all mRNA (RNA-seq) present in the 
BM of our index patient as well as in CD34+ cells from a normal control. In the 
presence of functional spliceosomal machinery, sequencing reads are expected not to 
cross the intron/exon boundaries and therefore should not contain any intronic 
sequences. Although no clear genome-wide increase in intron retention was observed 
in the patient, as previously reported by Makishima et. al. [125] in some MDS cases, 
we found an altered pattern of splicing in the mRNA species transcribed from the 
RUNX1 gene. At the 3’ splice site of RUNX1 intron 5, the un-spliced reads were almost 
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3 times more frequent in the mutated patient than the normal control (Figure 10). 
Because of the large numbers of diverse mutations in the splicing machinery, large 
studies will be needed to fully evaluate the impact of these mutations in splicing. 
 
Figure 10: Integrative Genome Viewer image from RNA-seq data. We found an altered pattern of 
splicing in the mRNA species transcribed from the RUNX1 gene. At the 3’ splice site of RUNX1 intron 5, 
the un-spliced reads were almost 3 times more frequent in the mutated patient than the normal 
control. 
4.2.5 Identification of PIM3/SCO2 fusion transcript 
Another putative effect of mutations in spliceossome machinery is the 
appearance of chimeric RNAs formed, as in a reciprocal translocation, by the junction 
of two originally distinct genes. To assess this kind of instability, we used our RNA-seq 
data. In fact, we identified a chimeric transcript involving PIM3 and SCO2 genes (both 
were located on 22q13.33), that was the result of an intrachromosomal inversion of 
approximately 0.6Mb in chromosome 22 (Figure 11). The PIM3 oncogene belongs to 
the Ser/Thr protein kinase family, and PIM subfamily. This gene is overexpressed in 
hematological and epithelial tumors and is associated with MYC co-expression. It plays 
a role in the regulation of signal transduction cascades, contributing to both cell 
proliferation and survival, and provides a selective advantage in tumorigenesis [126]. 
Interestingly, inhibition of PIM kinases by pim kinase inhibitors in Myc-induced 
lymphoma resulted in cell in cell death [127]. Functional studies are needed to 
elucidate the role of this fusion gene in leukemogenesis. 
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Figure 11: PIM3/SCO2 fusion gene. PIM3-SCO2 fusion gene result of an intrachromosomal inversion of 
approximately 0.6Mb in chromosome 22 
4.2.6 Gene expression profiling 
Finally, we also took advantage of the global expression profile that can be 
obtained from the RNA-seq data. We performed such analysis and identified the genes 
that were differentially expressed in the CNL cells compared with the normal CD34+ 
cells. We obtained 2022 genes upregulated and 1884 genes downregulated in CNL 
compared with the control (FDR=0.05). Interestingly, IKZF1, CEBPA, PDGFRA/B, IDH1, 
MAPK1, TET2, CDK2, MEIS2/3, and PBX3 were upregulated in our CNL in comparison 
with control and, among the downregulated, we observed IKZF2/3, HOX genes, 
UBE2G2, ASXL1, RUNX1/3, LUC7L2 and YES1. 
To describe the effects of these deregulated expressions, we performed an 
Ingenuity Systems Analysis, detailed in the Material and methods of this thesis (pg. 35). 
Functional classification of genes differently expressed between CNL cells and normal 
control (CD34+) revealed an enrichment of categories like cell signaling; cell death and 
survival; and gene expression (B-H p-value <0.05) (Figure 12). These findings 
reconfirmed the significant pathophysiology of such several synergetic unique genetic 
defects in the general CNL cohort, as well as in our index case. 
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Figure 12: IPA classification in CNL. Functional classification of genes differently expressed between CNL 
cells and normal control (CD34+), according to IPA, revealed an enrichment of categories like cell 
signaling; cell death and survival; and gene expression (B-H p-value <0.05). 
4.2.7 Clinical relevance of the mutation analysis 
The oncogenic CSF3R mutations T618I strongly activate the JAK/STAT pathway 
and are sensitive to inhibitors of SRC family-TNK2 and JAK kinases and may provide a 
new avenue for therapy [128]. On the other hand, pim kinase inhibition could be a 
viable treatment strategy in certain human leukemias that rely on PIM3 kinase 
expression [127]. In addition, epigenetic modifiers provide new targets for therapeutic 
intervention and targeting these enzymatic activities are currently being explored from 
a therapeutic standpoint in several types of leukemia [129, 130]. Although, Pardanani 
et al. considering 35 cases of clinically suspected CNL, did not found alteration in the 
survival based on the presence or absence of CSF3R mutations, our reported patient 
had a rapid disease progression and died seven months after diagnosis, probably 
explained by the profoundly aberrant landscape of gene mutations and 
rearrangements with functional effects on the biology of the tumor cells. 
In sum, our study provides, for the first time, a massive molecular and 
expression data, revealing a large amount of genomic alteration in CNL. In this complex 
scenario, a combination of new targets therapies may be considered as reasonable 
option for the therapeutic management of this aggressive and rare subtype of 
leukemia. 
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4.3 Part III: Blastic plasmacytoid dendritic cell neoplasm coding 
genome 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously referred as 
“blastic NK-cell lymphoma/leukemia” or “agranular CD4+/CD56+ hematodermic 
neoplasm”, is a rare and aggressive hematologic disease derived from precursors of a 
specialized subset of dendritic cells, and hence, after some discussion, is considered a 
myeloid-related disease according to the 2008 WHO classification of myeloid 
neoplasms [21, 41-46]. These tumor cells infiltrate skin, bone marrow (BM), peripheral 
blood (PB) and lymph nodes [47-50] and mainly affect elderly patients with the 
maximum incidence peaking at approximately 65 years of age.  
 Diagnosis is based on the immunophenotype of the blast cells that are 
characterized by the expression of CD4, CD43, CD56, CD123, BDCA-2/CD303, TCL1, and 
CTLA [51]. In addition, immunohistochemical markers, such as SPIB, BDCA-4, IRF-8, 
BCL11A and CD2AP, have been recently reported as tools for BPDCN diagnosis [51, 52]. 
There are no established genetic biomarkers that assist in the clinical management of 
BPDCN. Preliminary results from molecular studies suggest that abnormalities of genes 
known to confer a poor prognosis in other hematological malignancies, such as 
CDKN2A/CDKN2B, TET2 and TP53, are frequently seen in BPDCN [53, 54]. 
The overall prognosis for BPDCN is remarkably poor. Lymphoid-like 
chemotherapy is the preferred treatment, however, most patient relapse, resulting in a 
median overall survival (OS) of 12-14 months [55, 56]. Only high-dose therapy followed 
by allogeneic stem cell transplantation can provide durable control in this otherwise 
fatal condition [57, 58]. 
We designed a study to discover BPDCN-associated mutations based on 
sequencing the complete exome of 3 tumors, matched with normal samples. The 
discovered mutations detected were then further studied in an expanded cohort. These 
efforts led to the identification of several important disease associated mutations, the 
reconstruction of the genetic pathways underlying the BPDCN pathogenesis, and 
revealed associations between genetic events and clinically important features of the 
disease. 
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4.3.1 Mutations in coding sequencing by WES in BPDCN 
To improve our understanding of the genes involved in the pathogenesis and 
clinical evolution of BPDCN, WES was performed on matched tumor and normal 
samples from 3 individuals with BPDCN. The bioinformatics analysis and the filtering 
steps to identify the coding variants are detailed in the Material and Methods chapter 
of this thesis (pg.34). In total, we found 509, 590 and 1505 somatic alterations in case 
1, case 2 and case 3, respectively (Table 11). Among them, 347, 457 and 961 were 
intronic, respectively and therefore, excluded from further analysis. To gain insight into 
the genes affected by the leukemic process in BPDCN, we focused our research on the 
mutations that passed our quality control and were predicted to result in protein-
coding changes, identifying a total of 347 mutations in 81 affected genes. The 
distribution of numbers and categories of somatically acquired exonic mutations and 
indels is represented in Figure 13.  Unfortunately, when we crossed these 81 affected 
genes, we did not identify a common mutated gene between patients (Figure 14). Of 
interest, however, we identified, for the first time, deleterious mutations in IKZF3 
(IKAROS family zinc finger 3 - Aiolos), HOXB9 (homeobox B9), UBE2G2 (ubiquitin-
conjugating enzyme E2G 2) and ZEB2 (zinc finger E-box binding homeobox 2) in human 
leukemia. 
Table 11: SNVs filtering steps of BPDCN WES 
Filter Case1 Case2 Case3 
Total 3306 3839 9683 
Somatic 509 590 1505 
Exonic 162 133 544 
Consequence* 63 59 240 
Quality Control 28 8 49 
*Frameshift, stop gain and non-synonymous-deleterious 
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Figure 13: Distribution of the numbers and categories of somatically acquired exonic mutations and 
indels among the 3 cases studied by WES. In total, we found 509, 590 and 1505 somatic alterations in 
case 1, case 2 and case 3, respectively. Among them, 347, 457 and 961 are intronic, respectively. 
 
Figure 14: Venn diagram showing that there is no common mutated gene between patients (Exonic, 
frameshift, stop gain/loss and no synonymous mutations-deleterious; QC>200). 
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A functional clustering analysis of the mutated genes, using IPA software 
(Material and Methods pg. 35), showed a substantial enrichment of pathways involved 
in dermatological diseases and conditions, genetic disorder and hematological disease, 
among others (Figure 15). Looking in detail at the list of mutated genes within the 
hematological disease pathway, we observed that they have functions involved in DNA 
methylation (TET1 and TET2), chromatin remodeling (ASXL1) and RNA splicing (U2AF1); 
all of which have previously been reported as mutated in myeloid neoplasms. These 
data suggested that BPDCN has a mutational profile similar to that of other well-
defined myeloid leukemias.  
 
Figure 15: IPA classification in BPDCN. Substantial enrichment of pathways involved in dermatological 
diseases and conditions, genetic disorder, hematological disease, among others. 
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4.3.2 Screening for somatic mutations in regions recurrently altered in 
myeloid neoplasm by targeted next-generation sequencing 
Taking the previous results into consideration, we decided to use a targeted re-
sequencing approach to study these three pathways as well as transcription factors, 
protein kinase and ubiquitination genes involved in myeloid malignancies in a larger 
validation cohort of BPDCN samples. In detail, we applied a comprehensive and cost-
effective target resequencing approach to indentify mutations in the coding sequences 
of 38 selected genes which are prone to harbor mutations involved in leukemogenesis 
(n=25) and have been identified in our previous analysis (n=13) (Table 5 on Material 
and Methods section). This panel is composed of genes from nine categories: DNA 
methylation (5 genes), chromatin remodeling (4 genes), transcription factors (10 
genes), splicing machinery (5 genes), protein kinase activity (6 genes), ubiquitination (4 
genes), RAS family (2 genes), nucleophosmin (1 gene) and tumor suppressor (1 gene). 
We included a total of 39 BPDCN tumour DNAs of which, after quality control for 
library preparation, 25 cases were suitable for analysis. On average, 98% of reads 
mapped uniquely to the target sequences, and we obtained 93% mean target coverage 
with an average read depth of 471 reads per base. 
The bioinformatics analysis and the filtering steps to identify the coding 
variants are detailed in the Material and Methods chapter of this thesis (pg.36). After 
filtering out changes in the intronic regions and polymorphisms (present in dbSNP132), 
we identified a total of 141 variants in all sequenced exons of the 25 BPDCN patients, 
an average of 5.64 mutations per case. After discarding alterations in noncoding RNAs 
(ncRNAs), the 5’ or 3’ untranscribed regions (UTRs), and synonymous mutations, only 
90 single nucleotid variants (SNVs) and indels resulted in an amino acid change, 
frameshift or stop codon (Table 12). We selected 52 SNVs/indels for validation by 
Sanger sequencing that showed frequencies above 20% and we were able to confirm 
91% of the variants. In addition, with this resequencing strategy, we were able to 
detect all the alterations found in the three patients studied by WES, confirming the 
suitability of the panel for discovering genetic defects in the extension cohort. 
Based on the pathogenic alterations, we observed mutations in 29 genes and a 
mean of 3.6 mutations per case. The extreme cases were one patient with 7 and 
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another two patients with no pathogenic alterations in the 38 studied genes (Figure 
16A).  TET2 was the most frequently mutated gene (36%), followed by ASXL1 (32%), 
NRAS (20%) and NPM1 (20%), the IKAROS family (20%) and ZEB2 (16%). In TET2, we 
identified ten heterozygous variants (4 frameshift, 4 nonsense and 2 missense 
changes) spread across the coding exons of the gene in nine patients. The frameshift 
p.Ile490Tyrfs*14 was found in two individuals and one patient had two different TET2 
mutations. ASXL1 presented heterozygous mutations, mostly clustered in exon 12, in 
six patients. However, two mutations were found in exon 11. The majority of ASXL1 
mutations were frameshift (n=6). Alterations in the NPM1 gene were found in exons 6 
and 12. One of them was homozygous and two were present in more than one 
individual. All the mutations observed in NRAS were single AA changes, with three 
being in the known codon 12 and only one in codon 146 (Table 13). These data are in 
line with the mutational profiles reported for acute myeloid leukemia and other 
myeloid neoplasms [39].  
ZEB2 and IKZF3, transcription factors previously not reported as being mutated 
in human leukemias, were found to contain deleterious mutations in our BPDCN DNAs. 
ZEB2 codes for a zinc finger/homeodomain protein that normally functions as a DNA-
binding transcriptional repressor. We found two frameshift mutations and one single 
AA change in ZEB2). Finally, IKZF3 and other members of the IKAROS-family of genes 
were also recurrently mutated in BPDCN. One patient had a frameshift mutation in 
IKZF1, another had a single AA change in IKZF2 and three patients had alterations in 
IKZF3: one single AA change and one frameshift in two cases. Twenty percent of our 
BPDCN patients harbored mutations in IKAROS-family genes, suggesting a potential 
role of these genes in this specific type of myeloid leukemia. 
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Figure 16: Recurrently mutated genes and their interaction in BPDCN. (A) 25 total cases of BPDCN were screened for somatic variants in 13 genes 
identified by WES and in 25 genes previously reported to be mutated in myeloid malignancies (a total of 38 genes). Mutations are represented in red. We 
observed mutations in 29 genes, among them, TET2 is the most frequently mutated (36%), followed by ASXL1 (32%), NRAS (20%) and NPM1 (20%), 
IKAROS family (20%) and ZEB2 (16%). (B) The circos diagram depicts the relative frequency and pairwise co-occurrence of mutations in the BPDCN 
patients. The length of the arc corresponds with the frequency of mutations in the first gene, and the width of the ribbon corresponds to the percentage 
of patients who also had a mutation in the second gene. Pairwise co-occurrence of mutations is denoted only once, beginning with the first gene in the 
clockwise direction. Mutations in TET1-2 and IDH1-2 are mutually exclusive, as previously reported in other myeloid malignancies. 
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Because BPDCN is a rare disease that was recognized as a distinct entity only 
recently, information regarding genomic and genetic biomarkers is rather limited. 
Lucioni et al14 studied 21 BPDCN patients by comparative genomic hybridization arrays 
and found complete or partial chromosomal losses with common deleted regions 
involving the CDKN2A/CDKN2B, RB1, CDKN1B), LATS2 and IKZF1 loci. Jardin et al [54] 
reported 54% and 38% of TET2 and TP53 mutations, respectively, in the 13 BPDCN 
individuals studied. In this study, we present, for the first time, a comprehensive 
analysis of BPDCN combining next generation sequencing with clinical characteristics 
and clinical outcomes of 25 patients. Although we did not find a common alteration 
that could explain the pathogenesis of BPDCN in the three patients studied by WES, we 
identified deleterious mutations in IKZF3, HOXB9, UBE2G2 and ZEB2 for the first time 
in human leukemia and more common alterations such as TET1/2, ASXL1 and U2AF1 
previously reported as mutated in other myeloid neoplasms. 
The best test of the relevance of individual mutations for pathogenesis (in the 
absence of functional validation) is their recurrence in other samples or other cancers. 
TET2 mutations featured in our series appear similar to those observed in myeloid 
neoplasms: aberrations are mainly frameshift or nonsense and have been observed 
with the same frequencies (36-58%)[131]. However, our TET2 and TP53 mutation 
frequency are lower compared to the BPDCN cases from Jardin et al. Similar to other 
hematological malignancies, the relevance of TET2 mutations remains undetermined in 
this disease, which is characterized by a peculiar combination of various genomic 
alterations. Truncated exon 12 mutations in ASXL1 have recently been described in 
11% of patients with MDS, 43% of those with chronic myelomonocytic leukemia, 7% 
with primary and 47% with secondary AML [132]. The NPM1 mutations was previouly 
shown to be present in 23.5% of AML patients and activating RAS mutations were 
found to be present in 10.7% [76].  
Notably, only one BPDCN case displayed JAK2 and other FLT3-ITD mutations, 
reinforcing that BPDCN and acute myeloid leukemia (AML) or myeloproliferative 
disorders may be genetically distinct. Pointing out to these differences, we found 
mutations in genes never shown to be involved in human leukemia. First, the IKAROS 
gene family encodes zinc-finger transcription factors that regulate gene expression via 
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chromatin remodeling in lymphoid development and differentiation. In fact, IKZF1/2/3 
mutations are prevalent in acute lymphoblastic leukemia (ALL) [132, 133]. Since 20% of 
our BPDCN patients harbored mutations in IKAROS-family genes, a potential role of 
these genes in normal or abnormal myelopoiesis should be considered. Secondly, 
although mutations in ZEB2 have not been reported in human cancer, ZEB2 protein 
interacts with several members of the SMAD protein family that have been shown to 
play important roles in normal and malignant hematopoiesis. Finally, a preliminary 
report indicated that ZEB2 was overexpressed in leukemia patients with MLL gene 
rearrangements [134]. 
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Table 12: Pathogenic variants found using target next generation sequencing 
Position Gene Ref Variant Var Freq Coverage Sample Codon Change AA Change Type Provean SIFT
31022978 ASXL1 T TA 45,57 1457  Case_09 Frameshift NA NA
31024844 ASXL1 G GT 21,43 28  Case_11 Frameshift NA NA
31022898 ASXL1 TC T 42,51 1583  Case_14 Frameshift NA NA
31025066 ASXL1 AG A 21,43 392  Case_16 Frameshift NA NA
31021157 ASXL1 TTGTG T 41,2 716  Case_22 Frameshift NA NA
31021162 ASXL1 T A 42,9 613  Case_22 TTG TG[T/A] GTC C387* Nonsense NA NA
31023135 ASXL1 CCT C 50,95 997  Case_41 Frameshift NA NA
31022550 ASXL1 G T 49,66 149 Case_01 AGG [G/T]GA GGC G679* Nonsense NA NA
31024021 ASXL1 C CT 27,19 1927 Case_08 Frameshift NA NA
76939409 ATRX C T 5,32 282  Case_10 GGA [G/A]AA AAA E447K Single AA Change Neutral Damaging
76939409 ATRX C T 5,71 210  Case_11 GGA [G/A]AA AAA E447K Single AA Change Neutral Damaging
76888705 ATRX C G 70,59 17  Case_28 GCT TT[G/C] GTT L1708F Single AA Change Deleterious Damaging
76776372 ATRX G A 5,49 1966  Case_42 CTC T[C/T]A GAG S2365L Single AA Change Neutral Damaging
76812991 ATRX A C 5,17 2497  Case_42 ACT TT[T/G] GAG F2210L Single AA Change Deleterious Tolerated
105377837 CBLB C CG 16,07 168  Case_42 Frameshift NA NA
45296756 CBLC T C 8,54 199  Case_24 CCC T[T/C]C TGC F388S Single AA Change Deleterious Damaging
25457243 DNMT3A G A 36,4 684  Case_13 AGC [C/T]GC TTG R882C Single AA Change Deleterious Damaging
25536822 DNMT3A T G 52,94 17  Case_14 GGG G[A/C]C ACC D11A Single AA Change Neutral Damaging
11992124 ETV6 TG T 28,66 841  Case_06 Frameshift NA NA
11992124 ETV6 TG T 18,47 1202 Case_04 Frameshift NA NA
11992124 ETV6 TG T 26,2 1290 Case_08 Frameshift NA NA
148525964 EZH2 A AAC 19,44 36  Case_13 Frameshift NA NA
148525964 EZH2 A AAC 16,22 37  Case_14 Frameshift NA NA
148513776 EZH2 C T 41,4 372 Case_05 CAC C[G/A]G TTG R502Q Single AA Change Deleterious Damaging
148523616 EZH2 G C 29,92 1183 Case_05 TTA CA[C/G] TCC H279Q Single AA Change Deleterious Damaging
28602329 FLT3 G A 12,33 981  Case_11 GGG G[C/T]G TGC A680V Single AA Change Deleterious Damaging
46700467 HOXB9 C T 42,94 2718 Case_03 GCT C[G/A]C TCT R183H Single AA Change Deleterious Damaging
209113112 IDH1 C T 19,42 515  Case_13 GGT C[G/A]T CAT R132H Single AA Change Deleterious Damaging
90631934 IDH2 C T 14,87 2166  Case_13 ATC C[G/A]G AAC R140Q Single AA Change Deleterious Damaging
90631934 IDH2 C T 45,51 2516  Case_14 ATC C[G/A]G AAC R140Q Single AA Change Deleterious Damaging
90631934 IDH2 C T 5,54 1551  Case_18 ATC C[G/A]G AAC R140Q Single AA Change Deleterious Damaging
50450305 IKZF1 CA C 54,59 850  Case_06 Frameshift NA NA
213921691 IKZF2 G A 6,01 516  Case_25 GTG G[C/T]T GAC A97V Single AA Change Neutral Tolerated
37922598 IKZF3 C CG 25,11 1561  Case_13 Frameshift NA NA
37922621 IKZF3 C T 26,61 932 Case_01 GCC [G/A]AA GCC E318K Single AA Change Deleterious Damaging
37922598 IKZF3 C CG 26,49 906 Case_03 Frameshift NA NA
5054619 JAK2 T G 10,3 233 Case_08 ATT T[T/G]G ACA L224W Single AA Change Deleterious Damaging
55593690 KIT A T 4,64 3408  Case_28 CCC [A/T]GA AAC R586* Nonsense NA NA
25378562 KRAS C T 10,59 340  Case_07 TCA [G/A]CA AAG A146T Single AA Change Deleterious Damaging
25398282 KRAS C A 30,32 188  Case_07 GGT [G/T]GC GTA G13C Single AA Change Deleterious Damaging
25368410 KRAS C T 43,02 1311  Case_39 CCT [G/A]GC TGT G179S Single AA Change Neutral Damaging
170837544 NPM1 T TCTGC 33,71 264  Case_13 Frameshift NA NA
170819932 NPM1 T TTAG 100 30  Case_18 CTT [-/TAG] GCT L158* Nonsense NA NA
170819952 NPM1 AC A 19,16 214  Case_18 Frameshift NA NA
170819930 NPM1 C T 6,02 930  Case_28 AAA [C/T]TT GCT L158F Single AA Change Neutral Damaging
170837544 NPM1 T TCTGC 33,83 133 Case_03 Frameshift NA NA
170819930 NPM1 C T 5,83 103 Case_08 AAA [C/T]TT GCT L158F Single AA Change Neutral Damaging
115258747 NRAS C T 17,76 670  Case_16 GCA G[G/A]T GGT G12R Single AA Change Deleterious Damaging
115258748 NRAS C G 23,8 458  Case_18 GCA [G/C]GT GGT G12R Single AA Change Deleterious Damaging
115252204 NRAS C T 9,66 290  Case_41 TCA [G/A]CC AAG A146T Single AA Change Deleterious Damaging
115258747 NRAS C G 5,26 646 Case_04 GCA G[G/C]T GGT G12A Single AA Change Deleterious Damaging
115258747 NRAS C T 7,23 788 Case_08 GCA G[G/A]T GGT G12D Single AA Change Deleterious Damaging
36252864 RUNX1 T TCGAC 45,29 223  Case_09 Frameshift NA NA
198266476 SF3B1 AT A 19,52 210  Case_07 Frameshift NA NA
198266476 SF3B1 AT A 16,32 380  Case_14 Frameshift NA NA
198257842 SF3B1 A G 45,1 765  Case_28 GGT [T/C]GT GAA C1204R Single AA Change Deleterious Tolerated
74732959 SRSF2 G T 45,29 170  Case_14 CGC C[C/A]C CCG P122H Single AA Change Deleterious Damaging
74732959 SRSF2 G T 64,81 108 Case_08 CGC C[C/A]C CCG P122H Single AA Change Deleterious Damaging
70332921 TET1 C T 8,95 525 Case_02 TCA [C/T]GA GTA R276* Nonsense NA NA
106157044 TET2 C T 41,88 1466  Case_06 GAC [C/T]AA CAT Q670* Nonsense NA NA
106164901 TET2 A ACGCTCACCAAT 36,9 626  Case_07 Frameshift NA NA
106197378 TET2 A G 30 850  Case_07 CAG C[A/G]T AAG H1925R Single AA Change Deleterious Damaging
106180838 TET2 G T 39,33 300  Case_22 GGT T[G/T]T TCA C1310F Single AA Change Deleterious Damaging
106196345 TET2 T TA 37,59 689  Case_22 Frameshift NA NA
106156566 TET2 C CT 29 1000  Case_24 Frameshift NA NA
106196415 TET2 C A 39,23 808  Case_39 TCT T[C/A]A CAC S1604* Nonsense NA NA
106156566 TET2 C CT 56,34 994  Case_41 Frameshift NA NA
106158403 TET2 AATAATTTT A 36,54 572 Case_02 Frameshift NA NA
106164832 TET2 G T 53,87 1253 Case_03 TGG [G/T]AA GGA E1255* Nonsense NA NA
106193892 TET2 C T 27,58 765 Case_08 CGG [C/T]GA AAA R1473* Nonsense NA NA
7578536 TP53 T G 38,65 727  Case_07 AAC [A/C]AG ATG K132Q Single AA Change Deleterious Damaging
7577551 TP53 C T 62,63 835 Case_01 ATG [G/A]GC GGC G244S Single AA Change Deleterious Damaging
44514876 U2AF1 T C 9,02 4091  Case_25 GCG G[A/G]A AAG E124G Single AA Change Deleterious Tolerated
44514769 U2AF1 T TCTCATA 30,36 616  Case_41 GAG [-/TATGAG] ATG E159EYE Insertion Deleterious NA
44524456 U2AF1 G A 25,27 182 Case_02 TGC T[C/T]T CGG S34F Single AA Change Deleterious Damaging
46197270 UBE2G2 T A 28,68 129 Case_01 CTT G[A/T]T TAC D63V Single AA Change Deleterious Damaging
145156878 ZEB2 C CG 27,98 193  Case_18 Frameshift NA NA
145156878 ZEB2 C CG 23,91 46  Case_37 Frameshift NA NA
145161489 ZEB2 T TC 18,2 1000  Case_42 Frameshift NA NA
145157495 ZEB2 A C 36,05 491 Case_01 GGG C[T/G]T GGA L420R Single AA Change Neutral Damaging
15827389 ZRSR2 C T 59,74 77  Case_06 GAT [C/T]GA GCT R169* Nonsense NA NA
15834002 ZRSR2 A AG 17,42 666  Case_22 Frameshift NA NA  
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Table 13: The mutated genes in BPDCN 
Annotated gene Mutation type Position Allele change AA Change Case numbers with mutation Frequency (%)
Nonsense 106157044 C>T p.Gln649* 1 / 25
Frameshift 106164901 A>ACGCTCACCAAT p.Arg1262Serfs*8 1 / 25
Single AA Change 106197378 A>G p.His1904Arg 1 / 25
Single AA Change 106180838 G>T p.Cys1289Phe 1 / 25
Frameshift 106196345 T>TA p.Tyr1560* 1 / 25
Frameshift 106156566 C>CT p.Ile490Tyrfs*14 2 / 25
Nonsense 106196415 C>A p.Ser1583* 1 / 25
Frameshift 106158403 AATAATTTT>A p.Asn1103Argfs*24 1 / 25
Nonsense 106164832 G>T p.Glu1234* 1 / 25
Nonsense 106193892 C>T p.Arg1452* 1 / 25
Frameshift 31022978 T>TA p.Thr822Asnfs*11 1 / 25
Frameshift 31024844 G>GT p.Leu1444Serfs*3 1 / 25
Frameshift 31022898 TC>T p.Trp796Glyfs*22 1 / 25
Frameshift 31025066 AG>A p.Gly1518Alafs*23 1 / 25
Frameshift 31021157 TTGTG>T p.Cys387Serfs*74 1 / 25
Nonsense 31021162 T>A p.Cys387* 1 / 25
Frameshift 31023135 CCT>C p.Pro874Hisfs*5 1 / 25
Nonsense 31022550 G>T p.Gly679* 1 / 25
Frameshift 31024021 C>CT p.Leu1170Phefs*12 1 / 25
Frameshift 170837544 T>TCTGC p.Trp288Cysfs*12 2 / 25
Nonsense 170819932 T>TTAG p.Ala159Argfs*35 1 / 25
Frameshift 170819952 AC>A p.Asp165Glufs*28 1 / 25
Single AA Change 170819930 C>T p.Leu158Phe 2 / 25
Single AA Change 115258747 C>T p.Gly12Asp 2 / 25
Single AA Change 115258748 C>G p.Gly12Arg 1 / 25
Single AA Change 115252204 C>T p.Ala146Thr 1 / 25
Single AA Change 115258747 C>G p.Gly12Asp 1 / 25
IKZF1 Frameshift 50450305 CA>C p.Ile164Serfs*29 1 / 25
IKZF2 Single AA Change 213921691 G>A p.Ala91Val 1 / 25
Single AA Change 37922621 C>T p.Glu318Lys 1 / 25
Frameshift 37922598 C>CG p.Thr326Hisfs*25 2 / 25
Single AA Change 145157495 A>C p.Leu420Arg 1 / 25
Frameshift 145156878 C>CG p.Gly626Arg 2 / 25
Frameshift 145161489 T>TC p.Asp268Argfs*12 1 / 25
HOXB9 Single AA Change 46700467 C>T p.Arg183His 1 / 25 1 / 25 (4%)
UBE2G2 Single AA Change 46197270 T>A p.Asp63Val 1 / 25 1 / 25 (4%)
IKZF3
5 / 25 (20%)
ZEB2 4 / 25 (16%)
ASXL1
NPM1
NRAS
TET2
8 / 25 (32%)
5 / 25 (20%) 
5 / 25 (20%) 
9 / 25 (36%)
 
4.3.3 Functional categorization of mutated genes 
We used circus diagrams to assess patterns of mutual exclusivity and co-
occurrence between sets of genes.  We identified mutually exclusive alterations that 
affect TET1/2 and IDH1/2; TET1/2 and DNMT3A; and between IKAROS family genes. 
Additionally, mutations in ASXL1 and DNMT3A rarely co-occurred in our samples, with 
only one case harboring mutations in both. A rare co-occurrence was also observed 
between the splicing genes with only one case having mutations in both SF3B1 and 
SRSF2 (Figure 16B and Figure 17). 
We also grouped mutations into larger sets or pathways and examined patterns 
of mutual exclusivity and co-occurrence between these groups (Figure 16A and Figure 
18). Out of the 25 samples, 23 (92%) contained at least one mutation in one of the 
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nine categories. The nine categories and how frequently they were mutated are: 
aberrant methylation (48%), chromatin remodeling (52%), transcription factors (44%), 
splicing (36%), protein kinase (16%), ubiquitination (12%), NPM1 (20%), RAS (28%) and 
TP53 (8%). Half of the tumors had mutations affecting the methylation profile and 
chromatin remodeling pathways, and 20% had mutations in genes in both pathways. 
Recently, a series of mutually exclusive mutations that affect TET2, IDH1 or 
IDH2 mutations, and potentially other as yet unidentified disease alleles, was reported 
[39, 135]. We observed the same pattern of mutual exclusiveness in our series and 
additionally between IKAROS genes.  
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Figure 17: Pairwise co-occurrence of (A) TET1-2 and (B) IDH1-2 mutations in BPDCN. A circos diagram 
depicts the relative frequency and pairwise co-occurrence of other mutations with TET1-2 or IDH1-
2 mutations in the entire cohort. The length of the arc indicates the frequency of mutations in the first 
gene, and the width of the ribbon represents the percentage of BPDCN patients with TET1-2 or IDH1-
2 mutations who bear the second gene mutation. Pairwise co-occurrence of mutations is denoted only 
once, beginning with the TET1-2 or IDH1-2 gene in the clockwise direction. 
 
Figure 18: Target NGS result by pathways. (A) A Circos diagram depicts the relative frequency and 
pairwise co-occurrence of mutations by pathways in the BPDCN patients. The length of the arc 
corresponds to the frequency of mutations in the first pathway, and the width of the ribbon 
corresponds to the percentage of patients who also had a mutation in the second pathway. Pairwise co-
occurrence of mutations is denoted only once, beginning with the first pathway in the clockwise 
direction; (B) Distribution of numbers and categories of unknown and pathogenic mutations among the 
25 BPDCN cases. We do not identify any unknown nor pathogenic mutations among case 12 and 29 in 
the 38 studied genes, however, in case 8 we found mutations in almost all the represented pathways. 
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4.3.4 Clinical relevance of aberrant methylation genes mutations 
The analysis of survival data from the study cohort revealed several significant 
differences among the patients. First, we found that the patients with mutations in 
genes in methylation pathways had a significantly reduced OS rate compared to 
individuals without mutations in these genes (median 11 months versus 79 months; 
p=0.047, Figure 19A). On the other hand, patients with mutations in ETV6 (p=0.022), 
TP53 (p=0.003), and N/HRAS (p=0.015) had either a statistically significant worse 
prognosis (Figure 20) or showed a trend in the same direction (p=0.073) when a 
mutation of IKZF1/2/3 was present. Taking into consideration the limited sample size, 
we also combined the subgroups based on the functional classes for the outcome 
analysis. Among the combinations with clinical interest, the worst clinically significant 
changes were those affecting the RAS family, TP53 and other transcription factors 
(median 15 months, versus 99 months for the non-mutated cases; p=0.013) (Figure 
19B). These data suggest that mutations in aberrant methylation genes represent a 
poor prognostic factor and are probably involved in the pathogenesis of BPDCN. 
 
Figure 19: Kaplan-Meier overall survival (OS) curves. (A) We observed a significant difference in the OS 
according to the mutational status of genes included in the DNA methylation class (P=0.047; mut: n=7 
and 11 months; wt: n=10 and 79 months); (B) We observed a significant difference in the OS according 
to the mutational status of genes included in the transcription factor class / TP53 / RAS (P=0.013; mut: 
n=10 and 15 months; wt: n=7 and 99 months). 
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Figure 20: Kaplan-Meier overall survival curves for ETV6 (p=0,022), TP53 (p=0,003), IKZF1/2/3 (p=0,073) 
and RAS (p=0,015). Patients with mutations in these genes had a reduced cumulative survival. As the 
number in each subgroup of patients with individual gene mutations was very small, we combined the 
subgroups based on the functional classes for the outcome analysis. 
Correlation between epigenetic modifiers mutations and prognosis has been 
controversial. TET2 mutations are associated with poor prognosis in normal karyotype-
AML [136], but with no clear association in myelodisplastic syndromes (MDS) [137] or 
myeloproliferative neoplasm (MPN) [138]. Alterations in IDH1/2 are associated with a 
favorable or negligible effect on prognosis, depending on the type of mutation in AML 
[139, 140]. No importance was observed in MDS [137] or MPN [138, 141]. Several 
studies show that DNMT3A mutations are associated with worsened overall survival in 
patients with AML [70, 79] and an adverse prognosis in MDS [142]. In our series of 
BPDCN patients, we found that patients with mutations in genes in methylation 
pathways had a significantly reduced overall survival as compared with individuals 
without mutations in these genes. These data suggest that mutations in DNA 
methylation genes represent a poor prognostic factor but are likely to be involved in 
the pathogenesis of BPDCN. 
Changing the paradigm of what is known about BPDCN, our data suggest that 
this dendritic cell leukemia has a mutational profile strikingly similar to that of other 
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well-defined myeloid leukemias.  Despite the numerous advances in our understanding 
of the genetics and epigenetics of myeloid malignancies, only limited examples of 
clinical translation of these findings into new therapeutic approaches have been 
implemented. However, it has now become clear that epigenetic modifiers provide 
new targets for therapeutic intervention and that targeting these enzymatic activities 
are currently being explored from a therapeutic standpoint in several types of 
leukemia[129, 130]. Our study provides, for the first time, molecular data that suggest 
that a complete and innovative change is required in the treatment approach adopted 
for patients with BPDCN, including the administration of drugs that target aberrant 
methylation, chromatin remodeling, specific transcription factors and aberrant 
splicing. 
128 
 
129 
 
 
CHAPTER 5: Conclusions 
                     Conclusiones 
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•  We have been able to successfully apply next generation technologies to 
achieve deeper insights into the genetic pathogenesis of rare myeloid disorders 
and to integrate the obtained data in order to generate new and better genetic 
biomarkers that can be used in the clinical management these patients. In 
detail:  
• Whole-exome sequencing allowed the identification of a large number of 
mutated genes, some of them with prognostic and predictive significance, such 
as ASXL1 and TP53 in both chronic phase and blastic crisis of chronic myeloid 
leukemia. The study of the mutation profile through the course of the disease 
indicated that, at least in this patient, the number and the type of mutations 
were similar at chronic phase and blastic crisis. In addition, we identified for the 
first time deleterious mutations in IKZF3, UBE2G2 and ZEB2. 
• While current diagnostic procedures recommend the study of ABL1 mutations 
in non-responders chronic myeloid leukemia patients, our data suggest that 
sequencing a wider panel of genes, that includes ASXL1, TP53 and IKZF gene 
family, could be also beneficial in the clinical management of these patients.  
• In addition to the recurrent CSF3R mutation, we found and validated mutations 
in U2AF1, TET2, LUC7L2 and ASXL1 in a chronic neutrophilic patient. We also 
observed a large genomic segment displaying uniparental disomy in 
chromosome 7q, including the locus of LUC7L2, demonstrating a new 
mechanism of pathogenesis for this gene. Our study provides, for the first time, 
a massive molecular and expression data, revealing a large amount of genomic 
alterations in chronic neutrophilic leukemia. 
• Functional classification of genes differently expressed between chronic 
neutrophilic leukemia cells and normal control revealed an enrichment of 
categories like cell signaling; cell death and survival; and gene expression. 
• Although no clear genome-wide increase in intron retention was observed in 
the chronic neutrophilic leukemia cells, we found an altered pattern of splicing 
in RUNX1 gene. In addition, we identified an expressed fusion gene PIM3-SCO2 
that resulted from an inversion in chromosome 22. In conclusion, we show the 
concurrence of several genetic mechanisms of mutation that cooperate with 
the CSF3R mutation in chronic neutrophilic leukemia. In this complex scenario, 
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a combination of new targets therapies may be considered as reasonable 
option for the therapeutic management of this aggressive and rare subtype of 
leukemia. 
• Whole-exome sequencing of three patients with blastic plasmacytoid dendritic 
cell neoplasm revealed no common affected genes between patients, but a 
clear overlap in terms of molecular and disease pathways. Changing the 
paradigm of what is known about this disease, our data suggest that this 
dendritic cell leukemia has a mutational profile strikingly similar to that of other 
well-defined myeloid leukemias.   
• We successfully design and applied a comprehensive and cost effective 
targeted deep re-sequencing for screening 25 blastic plasmacytoid dendritic 
cell neoplasm tumors. Recurrence of many genes was found and ranged in 
prevalence from 36% for previously known genes, such as TET2, to 12-16% for 
newly identified genes, such as IKZF3 or ZEB2. Half of the tumors had mutations 
affecting the methylation profile and the chromatin remodeling pathways. 
• The analysis of clinical data from the blastic plasmacytoid dendritic cell 
neoplasm cohort revealed that patients with mutations in genes in the 
methylation pathways had a significantly reduced cumulative survival. Our 
study provides, for the first time, molecular data that suggest that a complete 
and innovative change is required in the treatment approach adopted for 
patients with blastic plasmacytoid dendritic cell neoplasm, including the 
administration of drugs that target aberrant methylation, chromatin 
remodeling, specific transcription factors and aberrant splicing. 
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• Hemos sido capaces de aplicar con éxito tecnologías de secuenciación completa 
de última generación para lograr una visión más profunda de la patogénesis 
genética de enfermedades mieloides raras. Además fuimos capaces de integrar 
los datos obtenidos con la finalidad de generar nuevos y mejores 
biomarcadores genéticos que se pueden utilizar en el manejo clínico de estos 
pacientes. En detalle: 
• La secuenciación del exoma completo permitió la identificación de un gran 
número de genes mutados, algunos de ellos con significado pronóstico y 
predictivo, tales como ASXL1 y TP53, tanto en la fase crónica como en la crisis 
blástica de la leucémia mieloide crónica. El estudio del perfil de mutacional a lo 
largo de la progresión de la enfermedad indica que, al menos en este paciente, 
el número y el tipo de mutaciones fueron similares en ambas fases. Además, se 
identificaron por primera vez mutaciones deletéreas en IKZF3, UBE2G2 y ZEB2. 
• Aunque los procedimientos de diagnóstico actuales recomiendan el estudio de 
mutaciones de ABL1 en pacientes con leucemia mieloide crónica no 
respondedores a los inibidores de las tirosina quinasas, nuestros datos sugieren 
que la secuenciación de un panel más amplio de genes, que incluyan ASXL1, 
TP53 y la familia de genes IKZF, podría ser también beneficiosa en el manejo 
clínico de estos pacientes. 
• Además de la mutación recurrente en CSF3R, encontramos y validamos 
mutaciones en U2AF1, TET2, LUC7L2 y ASXL1, en un paciente con leucémia 
neutrofílica crónica. También se observó una disomía uniparental en el brazo 
largo del cromosoma 7, incluyendo el locus de LUC7L2, lo que señala un nuevo 
mecanismo por la patogénesis de este gen. Nuestro estudio proporciona, por 
primera vez, un conjunto de datos moleculares y de expresión masivos, que 
revela una gran cantidad de alteraciones genómicas en la leucemia neutrofílica 
crónica. 
• La clasificación funcional de los genes diferencialmente expresados  entre las 
células de leucemia neutrofílica crónica y las del control normal reveló un 
enriquecimiento de categorías como la señalización celular, la muerte y 
supervivencia celular. 
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• Aunque no se observó un claro aumento en la inestabilidad global de los 
proceso de splicing en las células de la leucemia neutrofílica crónica, 
encontramos un patrón alterado de empalme en el gen RUNX1. Además, 
hemos identificado la expresión de un gen de fusión, PIM3-SCO2, que resultó 
de una inversión en el brazo largo del cromosoma 22. En conclusión, se 
demuestra la concurrencia de varios mecanismos genéticos que cooperan con 
la mutación en CSF3R en la leucemia neutrofílica crónica. En este complejo 
ensenario, una combinación de nuevas terapias específicas puede ser 
considerada como opción razonable para el manejo terapéutico de este subtipo 
agresivo y raro de leucemia. 
• La secuenciación del exoma de tres pacientes con neoplasia blástica de células 
dendríticas no reveló genes afectados comunes entre los pacientes, sino una 
clara superposición en términos de vías moleculares. Cambiando el paradigma 
de lo que se conoce acerca de esta enfermedad, nuestros datos sugieren que 
este tipo de leucemia de células dendríticas tiene un perfil mutacional 
sorprendentemente similar a la de otras leucemias mieloides bien definidas. 
• Diseñamos y aplicamos con éxito una re-secuenciación dirigida de un amplio 
panel de genes para la investigación de 25 tumores de neoplasias de células 
dendríticas. La recurrencia de muchos genes varió en la prevalencia del 36% 
para los genes previamente conocidos, como TET2, y el 12-16% para los genes 
recientemente identificados, tales como IKZF3 o ZEB2. La mitad de los tumores 
tenían mutaciones que afectan el perfil de metilación y las vías de 
remodelación de la cromatina. 
• El análisis de los datos clínicos de la cohorte de neoplasia de células dendríticas 
reveló que los pacientes con mutaciones en los genes en las vías de metilación 
tenían una supervivencia acumulada significativamente reducida. Nuestro 
estudio proporciona, por primera vez, los datos moleculares que sugieren que 
se requiere un cambio completo e innovador en el enfoque de tratamiento 
adoptado para los pacientes con neoplasia de células dendríticas, incluyendo la 
administración de fármacos que se dirigen contra la metilación aberrante y 
remodelación de la cromatina. 
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